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Abstract 
Deciphering properties of proteins is essential for improving human health and aiding in 
the development of new pharmaceuticals. While many investigations have focused on 
protein structures, it is equally important to probe protein dynamics, because 
conformational fluctuations are often intricately connected with protein function. This 
dissertation uses hydrogen-deuterium exchange (HDX) mass spectrometry (MS) and 
molecular dynamics (MD) simulations to study protein dynamics, for improving the 
understanding of protein folding/unfolding mechanisms, and to uncover aspects related to 
ligand binding and allosteric regulation. The common thread throughout this thesis is that 
previous studies have greatly underestimated the role of conformational fluctuations for 
the function of the three proteins studied in this work (and likely for many other proteins 
as well). 
Proteins possess surfactant-like properties, resulting in a high affinity for gas/water 
interfaces. Chapter 2 uses HDX-MS for probing the conformational dynamics of 
myoglobin (Mb) in the presence of N2 bubbles. HDX/MS relies on the principle that 
unfolded and/or highly dynamic regions undergo faster deuteration than tightly folded 
segments. In bubble-free solution Mb displays regular dynamics as under the native 
environment. However, in the presence of N2 bubbles, some mixed dynamics take place 
which shows protein are in native/semi-denaturing environments. To explain the observed 
deuteration kinetics, we propose a dynamic model that quantitatively reproduces the 
experimentally observed data: “semi-unfolded”  “native”  “globally unfolded”  
“aggregated”.  
Chapter 3 focuses on osteoprotegerin (OPG), which acts as a receptor activator of nuclear 
factor κB ligand (RANKL) decoy receptor and hinders bone resorption by inhibiting the 
interaction between RANKL and its binding partner, receptor activator of nuclear factor 
κB (RANK). OPG exists as monomer and dimer, both of which are biologically active. The 
transformation between monomer and dimer can be regulated by heparan sulfate (HS), but 
the details of this regulatory processes remains unclear. OPG undergoes fast EX2 exchange 
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which reveals the high dynamics of the protein. Site-specific changes in HDX rates 
accurately identify the HS and RANKL binding regions. Our HDX data also discovered 
that the RANKL binding patterns are somewhat different for OPG dimers and monomers. 
A mechanism is proposed for formation of the RANKL/OPG/HS ternary complex, 
according to which HS-mediated C-terminal contacts on OPG lower the entropic penalty 
for RANKL binding.  
Chapter 4 represents the center piece of this thesis. It explores the allosteric regulation of 
S100A11, a dimeric EF-hand protein with two hydrophobic target binding sites. An 
annexin peptide (Ax) served as the target. The allosteric mechanism was probed by 
HDX/MS, complemented by microsecond MD simulations. Consistent with experimental 
data, MD runs in the absence of Ca2+ and Ax culminated in target binding site closure. In 
simulations on [Ca4 S100] the target binding sites remained open. These results capture the 
essence of allosteric control, revealing how Ca2+ prevents binding site closure. Both 
HDX/MS and MD data showed that the metalation sites become more dynamic after Ca2+ 
loss. However, these enhanced dynamics do not represent the primary trigger of the 
allosteric cascade. Instead, a labile salt bridge acts as an incessantly active “agitator” that 
destabilizes the packing of adjacent residues, causing a domino chain of events that 
culminates in target binding site closure. Overall, this thesis highlights how the 
combination of HDX/MS and computational techniques can provide detailed insights into 
the nature of protein conformational fluctuations, and their implications for protein 
function, 
Keywords: protein dynamics | hydrogen-deuterium exchange | mass spectrometry | 
myoglobin | osteoprotegerin | S100A11 | molecular dynamics simulation  
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Chapter 1: Introduction 
 
1.1 Proteins 
 
Proteins are among the most important macromolecules in living organisms. Together with 
polysaccharides, nucleic acids, and membrane lipids, proteins participate in almost every 
biological process. For example, many proteins act as enzymes that catalyze chemical 
reactions associated with metabolism. Also, proteins can mediate structure and movement, 
e.g., actin and myosin in muscle cells and tubulin in microtubules. Some proteins are 
involved in cell signaling, immune response, and cell cycle control. Protein research is a 
highly interdisciplinary field that spans across chemistry, biology, pharmacology, physics, 
and engineering.1-3 
 
1.1.1 Protein Structure 
 
Proteins are polymers consisting of amino acids. The amino acid sequence constitutes the 
primary structure, and it is determined by the corresponding gene (Figure 1a). Protein 
chains spontaneously fold and form higher order structures. The most common two 
secondary structures are α-helix (Figure 1b) and β-sheet. These secondary structure 
elements can further assemble into tertiary structure. One main driving force for forming 
tertiary structures is the hydrophobic effect, but other contacts such as salt bridges, 
disulfide bonds, and hydrogen bonds also help stabilize tertiary structure (Figure 1c), 
thereby defining the ways in which the protein folds and functions. In some cases, several 
folded chains assemble and form a quaternary structure (Figure 1d) that is capable of 
performing complex biological functions. For example, ATP synthase, the enzyme creates 
ATP in cells, has over 20 subunits.4 Also, some proteins accommodate cofactors such as 
heme groups in the case of hemoglobin and myoglobin. 
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Figure 1. Levels of protein structures. (a) primary structure: single letter residues codes 
are used to represent the amino acid sequence. (b) secondary structure: α-helix with a kink 
is used as an example. (c) tertiary structure; deoxyhemoglobin α-subunit. (d) quaternary 
structure: full tetramer structure of deoxyhemoglobin. (PDB:2hhb)5 
 
For correctly performing biological functions, proteins need to reach their “proper” (native) 
conformation. As an example, in trypsin a properly structured S1 catalytic pocket is 
essential for peptide/protein cleavage.6 (Figure 2) Trypsin can only perform its function 
when catalytic residues are located correctly. How can proteins precisely fold into these 
delicate structures? How are proteins able to adopt these complicated conformations from 
a simple linear sequence of amino acids? These questions have intrigued scientists for 
many decades. In 1969, Cyrus Levinthal pointed out his famous “Levinthal’s paradox”.7 
Hypothetically, if a protein is composed of 100 amino acids and each residue can adopt 
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33 conformations (via rotation of N-Cα bonds and C-CO bonds), the protein would have 
roughly 3200 ≈ 1095 possible conformation. Levinthal initially envisioned that protein 
folding is a random search process. If the protein were able to survey 1010 conformations 
per second finding its native state would require around 1077 years which is longer than the 
existence of the universe (15 billion years). It is concluded that the folding of proteins 
cannot be achieved through random conformational searches. A more efficient mechanism 
must exist.  
 
Figure 2. Trypsin catalytic amino acids at S1 pocket. 
 
Folding funnel/energy landscape theory is the most successful hypothesis so far for solving 
Levinthal’s paradox. (Figure 3) Imagine a ball sitting on a sloped surface, naturally, driven 
by the gravitational potential energy the ball would roll downhill to the lowest point on the 
surface. A similar thing also happens in the case of proteins: while a protein is fully 
unfolded and exists as a random coil, it has a high free energy due to unfavorable  and ψ 
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angles (dihedral angles of the roation about Cα-N and C-Cα bonds), water-exposed 
hydrophobic residues, etc. The protein molecule has a tendency to transit to a conformation 
with lower free energy, akin to skiing down a slope from higher (energy) ground. Under 
this circumstance, aimless random conformational searching is suppressed. It makes 
protein folding possible in a short period (10-6 to 103 seconds)8. Also similar to skiing, there 
could be multiple pathways in protein folding. The folding path might pass through local 
minima where folding-intermediates or molten globules are generated. Eventually, the 
protein reaches the free energy minimum and finishes the folding process. Alternatively, if 
the protein pursues a wrong folding path, it may misfolded and/or aggregate.9 
The main driving force in protein folding is the hydrophobic effect which can be explained 
by using the “iceberg” model. Many residues in proteins are hydrophobic (valine, leucine, 
isoleucine, etc.). The existence of “iceberg”-like water molecules that is packed around 
these exposed hydrophobic sites greatly decreases the solvent entropy which represents an 
unfavorable scenanrio according to the second law of thermodynamics. The amount of 
“icebergs” can be minimized as hydrophobic residues in the protein get packed within the 
protein core during folding. Water molecules are then released back to the bulk solution 
and increase the entropy of the system. Folding is also driven by enthalpic factors such as 
the formation of new H-bonds, disulfide bonds, salt bridges and van der Waals contacts. In 
short, protein folding is driven by the tendency of the system to decrease its free energy. 
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Figure 3. Schematic energy landscape. Protein conformations are represented as red balls. 
It is assumed that thermal motion allows the protein to freely explore the energy landscape 
to reach a (global or local) minimum. Folding and aggregation can have many alternative 
pathways with different local minima and transition states.  
 
1.1.2 Protein Dynamics 
 
There is no doubt that proteins need to fold to correct structures in order to perform their 
biological functions. However, these structures is not static. Proteins in solution are an 
ensemble of many similar conformations that undergo rapid interconversion (protein 
dynamics). For example, multiple possible NMR-derived structures of S100A11 were 
superimposed in Figure 4; each of them contributes to the conformational ensemble that 
exists in solution. 
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Figure 4. 19 Superimposed NMR structures of S100A11. Green and cyan represent the two 
monomers in the protein complex (pdb code 1NSH).10 
 
Protein dynamics comprise events taking place on time scales from ps to minutes; and the 
amplitude can be small or large: from side chain rotation to global transitions between 
protein conformations.11,12 Potein dynamics are highly related to protein function. In 
enzymes, protein dynamics are believed to be the key for catalytic turnover.13,14 For 
example, in ATP synthase, the γ subunit (the central shaft) gets destabilized during 
catalysis15; and the dynamics of chymotrypsin are intensified during substrate turnover.16 
Protein-ligand interactions also affect protein dynamics, generally resulting in a 
stabilization in the vicinity of the binding site due to the formation of new intermolecular 
contacts. By monitoring such dynamic changes, it is often possible to locate ligand binding 
sites, e.g., in the context of epitope mapping and drug-protein interaction studies.17,18 In 
contrast, by studying the change of protein dynamic properties from ligand binding, 
researchers can obtain deeper insight on how ligands impact protein.19 For instance, the 
dynamics of ligand binding pocket can be studied by computational methods to direct the 
design of inhibitors.20,21  
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Studying protein dynamics is not straightforward because it is nearly impossible to “see” 
how proteins move. However, sophisticated and advanced instrumental and experimental 
designs are now capable of providing quite detailed insights. Nuclear magnetic resonance 
spectroscopy (NMR) and mass spectrometry (MS) are both capable of providing such 
information.22,23 More details are discussed in section 1.2.  
 
1.2 Traditional Methods for Studying Protein Structures 
 
1.2.1 UV/Vis Spectroscopy 
 
UV/Vis spectroscopy is a technique that measures the ability of a sample to absorb light. 
Its principle, Beer’s law, can be written as 
𝑙𝑜𝑔10
𝐼0
𝐼
= 𝐴 = 𝜀 ∙ 𝑙 ∙ 𝑐 
Equation 1.1 
where I0 is the initial light intensity; I is the light intensity after the light passes through the 
sample; A is the absorbance; ε is the wavelength-dependent extinction coefficient that is 
unique to the sample; l is the length of the light path in the cuvette, and c is the sample 
concentration. The most common use of UV/vis spectroscopy in protein research is to 
determine protein concentration. The protein’s extinction coefficient depends on the 
number of tryptophan, tyrosine and phenylalanine.24 Thus, protein concentrations can be 
obtained by measuring the absorbance at 280 nm.  
UV/Vis spectroscopy can also be used in study protein folding, this approach is most useful 
for proteins that contain UV-Vis active cofactors. In bacteriorhodopsin (BR), a retinal 
incorporates in the center of the protein. For native BR in the purple membrane an 
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absorbance maximum shows at 568 nm, indicating the retinal is covalently bound to 
Lys216.25 In a denaturing SDS environment, the absorbance spectrum is blue-shifted to 
392 nm indicating the disruption of the native retinal-protein linkage.26 The straightforward 
nature of UV-Vis spectroscopy causes it to be widely used for protein studies. However, 
only limited structural information is obtainable in this way. 
 
1.2.2 Circular Dichroism (CD) Spectroscopy 
 
Similar to UV-Vis spectroscopy, CD also measures the difference of light before and after 
passing through the sample. However, CD monitors another light property, polarization. 
Light can be circularly polarized clockwise (right, R) or counter-clockwise (left, L). While 
polarized light passes through the sample, any chiral center will have different absorbance 
for L and R polarized light (AL, AR). The difference of AL-AR is what constitutes a CD 
spectrum. The far-UV region, between 180 nm and 250 nm in the CD spectrum reports on 
secondary structure: Two negative peaks (222 and 208 nm) and one positive peak (192 nm) 
represent α helices ; parallelly, one negative peak (218 nm) and one positive peak (195 nm) 
serve signs as β sheet; one negative peak at 195 nm reflect the presence of random coil.27,28 
Examples of CD far-UV spectra are shown in Figure 5. However, despite its widespread 
use, CD spectroscopy still cannot yield residue/atom level structural information. 
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Figure 5. CD spectra of proteins with characteristic secondary structure.29 Respectively, 
(1) a-helix; (2) β-sheet; (3) random coil.30 
 
1.2.3 X-ray Crystallography 
 
X-ray crystallography has been the gold standard in protein biophysics for many years. It 
can provide high-resolution structural information (down to 0.9 Å resolution). Under 
optimal conditions it can even reveal the position of hydrogen atoms.31  
X-ray crystallography is based on diffraction. The X-ray wavelengths used for this purpose 
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are on the order of 0.1 nm, which is comparable to chemical bond lengths. This is the reason 
why X-rays can be diffracted while passing through a protein molecule. However, a single 
molecule usually cannot generate a diffraction signal strong enough to be recorded. In a 
protein crystal, a 3D array of the same molecule amplifies the diffraction signals and 
protein structures can be uncovered with the help of Fourier transform analyses. Roughly 
90% of all structures stored in the protein data bank (PDB) have been generated using X-
ray crystallography.32 
X-ray crystallography is good at revealing the precise 3D-structure of proteins all the way 
to very large (MDa) complexes. However, dynamic aspects are difficult to uncover.33,34 
Some protein intermediates have been trapped and crystallized, but that requires 
sophisticated experimental designs, complicated data analysis tools, and often sheer luck. 
In general, crystallization of proteins can be challenging and time-consuming.35 Growing 
high-quality crystals of a new protein can take years even with the help of automated high 
throughput systems.36  
 
1.2.4 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
NMR might be the most widely used principal analytical technique. Its research objects 
include almost everything in chemistry: from small molecules to polymers, from solution 
to solid, from inorganic to biological molecules. The spin of atomic nuclei creates a 
magnetic moment. When the atom is placed in a strong magnetic field, the magnetic 
moment of the nucleus can be aligned with the external magnetic field in a parallel or 
antiparallel fashion and therefore create an energy split (Zeeman effect). The spinning 
nuclei together create a net magnetization vector (M). M can be “tilted” away from its 
equilibrated position by well-tuned radio-frequency (RF) electromagnetic radiation and 
precess in its new orientation, thereby inducing a current in the detector (receiver coil). The 
electron cloud around the nuclei can shield the magnetic field effect on the nuclei and 
therefore alter the frequency and the amplitude of the current (chemical shift). Thus, NMR 
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can be used to study the chemical properties of the sample and reaction mechanisms. 
For protein studies, NMR takes on a distinctly important role. Benefiting from the 
instrumental and the experimental developments (i.e., 2D-NOESY, 3D-15N/13C NOSEY-
HSQC, etc.), NMR can also provide 3D protein structures. Over 10,000 protein structures 
in the PDB have been obtained using NMR.32 NMR can also be used for probing protein 
dynamics37, especially on intrinsically disordered proteins that are a considerable challenge 
for X-ray crystallography.38 The upper size limit in protein NMR is often around 30 kDa. 
However, with the help of sophisticated experimental design it is now possible to examine 
larger systems (over 200k Da).39,40 Unfortunately, such experiments often focus more on 
functional/dynamical instead of generating atomic level structures.41 The relatively high 
sample concentrations (often in the 100 M to 1 mM range) also limit NMR application to 
some degree, because such samples tend to aggregate. 
 
1.2.5 Cryo-Electron Microscopy (cryo-EM) 
 
Another technique that can provide protein structure is cryo-EM. The 2017 Chemistry 
Nobel Prize was awarded for the development of cryo-EM. In the words of the Nobel 
committee, cryo-EM has brought biochemistry “into a new area.” EM is not a new 
technique, and its application on biological systems can be traced back to the 1930/40’s.42,43 
However, biological samples cannot be directly viewed by EM in solution; sample 
dehydration or fixation is needed for EM. These sample preparation steps may introduce 
artifacts. Cryo-EM solves this problem and makes the observation of “aqueous samples” 
possible. The principle of cryo-EM is to cool the sample to below liquid nitrogen 
temperature quickly. The cooling process is so fast that vitreous ice is formed instead of 
regular crystalline ice, and the structures of biological molecules can be well preserved. 
Molecules in vitreous ice are randomly oriented and leave a “trace” image by interacting 
with the electron beam. 3D molecular structures can be obtained by combining thousands 
of images through computer programs. Cyro-EM does not require crystallized samples, 
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and this important feature makes getting some challenging protein structures possible, e.g., 
membrane protein complexes. (Figure 6) Recent improvements of the charge coupled 
device (CCD) detectors and computing algorithms used for cryo-EM have dramatically 
enhanced the resolution of this technique to near X-ray crystallography level (from ~20 Å 
to below 4 Å).44 All these developments make cryo-EM a very attractive tool for protein 
structural biology. However, the ~US$ 10M price tag on cryo-EM instruments limits its 
application.45 
 
Figure 6. Structure of mammalian respiratory complex I (NADH: ubiquinone 
oxidoreductase). Complex I is one of the largest complexes in the mammalian cell and 
contains over 45 subunits. This model was generated by cryo-EM (Resolution 4.16 Å, pdb 
file 5LDW).46 
 
1.3 Mass Spectrometry 
 
Mass spectrometry (MS) has been a vital analytical tool in chemistry, biology, and other 
areas for many years. In the early 20th century, MS first demonstrated the existence of 
isotopes.47 After nearly a century of development on instrument and data analysis, MS can 
now reach a resolution of ~1 million. This high resolution dramatically expands the usage 
of MS from identifying small molecules48 to characterizing complicated protein 
complexes.49 MS can be coupled with chromatographic separation techniques such as 
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liquid chromatography (LC), gas chromatography (GC) and capillary electrophoresis (CE), 
etc. Also, multiple components (collision cells, ion mobility modules, etc.) can be 
combined with MS, and these tools provide additional dimensions of information.  
Generally, MS can be divided into several key parts: an ion source, a mass analyzer, and 
an ion detector (Figure 7). The following sections will briefly explain the basis of MS. 
 
Figure 7. Schematic of a mass spectrometer 
 
1.3.1 Ion Source 
 
1.3.1.1 Electrospray Ionization (ESI) 
 
MS can be imaged as a precise “balance” for measuring the mass (more accurately, the 
mass-to-charge-ratio m/z) of molecules and atoms. But no single molecule or atom can be 
really “put” on a balance to measure: analytes need to be ionized first and transferred into 
the vacuum of the mass analyzer. Various types of ion sources are commercially available. 
Each type has its advantages and disadvantages. For biological samples, electrospray 
ionization (ESI) represents the most successful and widely adopted ionization technique. 
ESI can transform solution phase molecules into gas phase ions. Therefore, ESI can 
interface with high performance liquid chromatography (HPLC) and ultra performance 
liquid chromatography (UPLC). This feature greatly extends MS application in analytical 
chemistry. Also, ESI is a “soft” ionization technique which means it is capable of analyte 
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ionization without rupturing covalent bonds. In many cases, even the preservation of 
noncovalent contacts is possible, which is the basis of native MS experiments.50  
The basic layout of an ESI source is shown in Figure 8. The sample solution is pumped 
through a metal capillary which is attached to a high voltage supply (±2~6 kV).51 The 
strong electrical field at the tip of the capillary creates a Taylor cone. At the tip of the cone, 
caused by Coulumbic repulsion which overcomes the surface tension, a mist of droplets 
that are enriched in charged analytes is ejected. With the help of source heating and a flow 
of nebulizing gas, droplets quickly shrink and vaporize to transfer charged ions into the gas 
phase for downstream analysis. 
 
 
Figure 8. Schematic layout of an ESI source (positive mode). Charge and analytes (i.e., 
protein) are represented in blue and red, respectively. The flow of electron is indicated by 
arrow. G denotes the grounded wire.  
An example of an ESI mass spectrum is shown in Figure 9. A typical attribute of the 
spectrum is the presence of multiple charge states. The mass to charge ratio m/z of a 
specific ion is given by 
m
z
=  
𝑀 + 𝑧 × 1.008
𝑧
 
Equation 1.2 
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where z is the (variable) charge state; M is the mass of the neutral analyte, and 1.008 refers 
to the proton mass (in Da). This equation assumes that the analyte charge is entirely due to 
protonation. 
 
Figure 9. ESI mass spectrum of apo-myoglobin. The charge states of each peaks are 
denoted in red. 
 
The presence of high charge states can be advantageous for large analytes: a high mass is 
converted to a much lower m/z value. This is important since many mass analyzers have a 
limited m/z range. However, high charge states can also turn into a disadvantage as the 
spectrum can become overly complicated, thereby creating the need for higher resolution 
mass analyzers.   
How ions are transferred from the aqueous phase to the gas phase during the ESI process 
is a particularly interesting question. Several models have attempted to explain the ESI 
process for various analytes.52 The first of these is the ion evaporation model (IEM, Figure 
10a).53 The IEM is generally assumed to explain the behavior of small molecule analytes. 
After the charged droplets leaves the Taylor cone, the droplet size keeps decreasing due to 
solvent evaporation, and the charge density of the droplet increases until the Coulombic 
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repulsion overcomes surface tension. This situation is referred as Rayleigh limit, which can 
be described as using the equation54  
𝑧𝑅 =  
8𝜋
𝑒
√𝜀0𝛾𝑟3 
Equation 1.3 
where zR is the number of charges; e = 1.60*10-19 C; ε0 is the vacuum permittivity, γ is the 
surface tension, and r is the radius of the droplet. The IEM envisions that once the droplet 
reaches the Rayleigh limit, charged analytes with low MW are ejected from the droplet 
surface. The other ESI model is charged residue model (CRM, Figure 10b).55,56 This model 
applies mainly to compact macromolecules (e.g., native proteins). While a (large) analyte 
is in a droplet near the Rayleigh limit, charges of the droplet are transferred to the analyte 
as the droplet evaporates to dryness.57 
Recently, Konermann et al. proposed an additional model58 that describes how unfolded 
proteins behave during ESI. Typically, a globular protein has a hydrophobic core and a 
hydrophilic surface. Once a protein gets denatured (e.g., in formic acid from the mobile 
phase in UPLC/LC), its hydrophobic residues in the core become solvent accessible as the 
chain unravels. In this case, and the protein migrates to the surface of the droplet for 
minimizing the contact with water molecules.52 Then the unfolded protein gets ejected from 
the droplet due to Coulombic repulsion.59,60 This model is referred to as chain ejection 
model (CEM, Figure 10c). 
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Figure 10. Summary of three ESI mechanisms (a) IEM: small molecular weight analyte 
gets ejected from ESI droplet, (b) CRM: a globular folded protein gets released into the 
gas phase, (c) CEM: an unfolded protein molecule is ejected into the gas phase from the 
droplet.59  
 
1.3.1.2 Other Ionization Techniques 
 
ESI is vital for biological samples, but it is not the only ionization technique. Besides ESI, 
many other ionization sources are available: these include electron ionization (EI), 
chemical ionization (CI), atmospheric pressure chemical ionization (APCI), matrix-
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assisted laser desorption ionization (MALDI), desorption electrospray ionization (DESI), 
paper spray (PS) ionization and several others. All these techniques have their unique 
strengths and features. EI and CI are considered to be “traditional” ionization techniques 
that are used mostly for small molecules (a few hundred Da) analytes. Extensive disruption 
of covalent bonds is the norm with these techniques, which are considered to be quite 
harsh.61,62 APCI is similar to CI, but the ionization process happens at atmospheric pressure, 
which makes it suitable for LC-MS.63 MALDI is an ionization technique that uses laser 
pulses to create ions from analyte molecules within an energy-absorbing matrix.64 MALDI 
is mostly used for analyzing biomolecules, and it is also important for imaging 
applications.65 In DESI, a stream of ESI droplets hits a surface, picks up analytes, and 
brings them into the gas phase.66 PS is another variant of ESI. The sample in liquid form 
(blood, urine, saliva, etc.) is applied to a piece of paper that is kept at high voltage.67 The 
spray is formed at the tip of the paper sheet, and ions enter the MS just as in regular ESI. 
PS probably represents the cheapest high throughput ionization techniques.68  
 
1.3.2 Mass Analyzer 
 
After analytes are ionized, a mass analyzer is needed to for detection, ion manipulation, 
and ion counting such that a mass spectrum can be generated. Several different mass 
analyzers have been commercialized. Here will briefly discuss quadrupoles and time-of-
flight (TOF) instruments. 
 
1.3.2.1 Quadrupoles 
 
Quadrupole mass analyzers are small, simple, and low-cost. They have a reasonable 
resolution, mass range, and excellent sensitivity. Quadrupoles can also be used for other 
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purposes: precursor selection, collision cells, and ion guides. In a triple quadrupole mass 
spectrometer, three quadrupoles are aligned in series. The first (Q1) and third (Q3) ones 
are regular mass analyzers; the second one (Q2) is employed as a collision cell/ion guide. 
By setting the Q1 and Q3 into scan mode or setting them to specific m/z values, triple 
quadrupoles can perform different types of experiments.69  
Figure 11 shows the schematic principle of a quadrupole. As implied by the name, a 
quadruple is composed of four rods that are connected to power supplies. All four rods are 
linked to a combination of direct current (DC) and radio frequency (RF) voltage. By 
keeping the RF/DC ratio constant and scanning the voltage amplitudes, the whole m/z 
range can be explored. Alternatively, RF and DC can be set to specific fixed values for 
transmitting certain m/z values only. A quadrupole can also be set up to RF only mode (DC 
= 0). In this case, the quadrupole behaves as an ion guide, and all almost all ions pass 
through.70  
 
 
 
Figure 11. Schematic of quadrupole operation. The ion path is demonstrated in blue and 
red. Red line: detected ions with the stable trajectory. Blue line: undetected ion with an 
unstable trajectory. 
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1.3.2.2 Time of Flight Mass Analyzer (TOF-MS) 
 
TOF-MS is another widely used mass analyzer. It is robust and can have high resolution 
(over 20,000) at a relatively low cost.71 Figure 12 shows the schematic of an orthogonal 
acceleration TOF-MS. After the ion beam enters the pusher chamber, ions are accelerated 
by a pulsed electric field. This pulse gives all ions potential energy as governed by the ionic 
charge. The potential energy is then transformed into kinetic energy. Thus, ions with 
different m/z have different velocities. By measuring how long ions travel from pusher to 
detector, the m/z of the ion can be determined. 
The following equation directs the TOF operation: 
 
√
𝑚
𝑧
=
𝑡√2𝑒𝑈
𝑙
 
Equation 1.4 
where U is the pusher voltage, l is the path length, and t is the time of flight in the instrument. 
For traditional TOF instruments, the path length is the length of the apparatus (as knowns 
as “linear TOF”).72 With the application of a reflectron (Figure 12), the resolution is 
dramatically improved. The reflection provides an electric field that reverses the direction 
of the ions. The reflectron not only increases the flight path length, but also corrects 
artifacts such as ions with the same m/z that have inadvertent kinetic energy differences 
created during acceleration in the pusher. The ions with higher kinetic energy penetrate 
deeper into the reflectron, such that their flight time becomes slightly longer. In this way 
the kinetic energy variation is compensated, and the resolution of the mass analyzer is 
greatly enhanced.  
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Figure 12. Schematic layout of a TOF mass analyzer (see text for details).  
 
1.3.3 MS Approaches to Study Biological Molecules   
 
Various MS techniques are available that can cover multiple areas including protein 
structure, kinetics, and dynamics. The conceptually simplest approach is known as “native” 
ESI-MS. It takes advantage of ESI as a soft ion source which can preserve native protein 
structures and interactions in the gas phase.50 By analyzing the mass spectrum of protein 
complexes under native condition, protein-protein/ligand binding stoichiometry can be 
uncovered.73 Another technique for characterizing the structure of multi-subunit proteins 
is chemical cross-linking.74 In this technique, bifunctional coupling reagents that react with 
amino acid side chains preform linking reactions. By digesting crosslinked protein and 
analyzing the tryptic peptides, protein/complex structural models can be built.75  
Chemical labeling is another technique that gains more and more traction in biological MS. 
This approach can be divided into selective chemical labeling and nonselective chemical 
labeling. For the former, chemical tags that react with specific amino acid side chains 
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(cysteine, lysine, arginine, etc.) are used to label proteins.76 The labeling pattern is 
dependent on solvent accessibility of the side chains, and their intrinsic reactivities.77 
Nonselective chemical labeling can universally tag all (or most) of the solvent-exposed 
amino acids on a protein. The most common nonselective labeling reagent is hydroxyl 
radical (HO•).78 With its universality, the mapping of protein solvent accessibility can be 
achieved in a single experiment.79  
 
1.4 Hydrogen-Deuterium Exchange (HDX) 
 
1.4.1 History 
 
The use of hydrogen-deuterium exchange (HDX) can be traced back to Linderstrøm-
Lang’s work in the 1950s.80 In their work, many fundamental concepts such as EX1 and 
EX2 exchange, fast exchange in the amino acid side chain, acid and base catalysis, etc. 
have been proposed. These concepts have been used to direct the HDX field until today. 
The detection methods of HDX kept getting developed. In the 1980s, it has already been 
possible to obtain site-resolved exchanging kinetics through NMR.81 Over the past 20 years, 
MS has entered the HDX field. Johnson and Walsh pioneered to use ESI-MS to measure 
HDX rates.82 They were the first to use LC-MS to measure the mass of deuterated peptides. 
This work laid the foundation of bottom-up HDX-MS. The easy operation and high 
efficiency of HDX-MS quickly made it the method of choice for most practitioners. 
Software was introduced to automate the data analysis.83 For improving throughput, the 
automated sample preparation84 and integration with UPLC85 were also applied around ten 
years ago. All these improvements built HDX-MS to become a powerful tool for protein 
dynamics study and was widely applied to elucidate various aspects: ligand binding, 
protein structure exploration, antigen justification, etc. HDX-MS is now well accepted in 
both academic and industrial laboratories.  
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1.4.2 Fundamentals of HDX 
 
In proteins, only hydrogens in O-H, N-H, and S-H are labile and can exchange with water 
hydrogens. This H-H exchange is not detectable by MS since there is no mass change. In 
contrast, when D2O is used as solvent, H-D exchange became measurable by MS since D 
is 1 Da heavier, and every HD exchange event will increase the protein mass. This 
exchange is bi-directional, which means D in the protein can also be replaced by solvent 
H. There is no fundamental difference between the two exchanges. Like most other studies, 
we will focus on exchange-in, where D replaces H. Back exchange (or exchange-out) refers 
to condition where the reverse scenario applies.  
In the amide backbone, HDX rates are slower by about two orders of magnitudes compared 
to those hydrogens in sidechains and protein termini.86,87 While hydrogens in amino acid 
side chains reaches exchange equilibrium in seconds, backbone amide hydrogen would 
take from minutes to hours, in some extreme cases even days, to achieve full equilibrium. 
Therefore, the exchange of side chain hydrogens is more challenging to measure and 
observe in MS since in LC-MS deuterium will be rapidly exchanged out when a gradient 
contained H2O is used. That makes backbone amide hydrogen the primary information 
carrier in HDX experiments.  
Why can HDX be used to study protein conformations and dynamics? This answer to this 
question can be ascribed into the activities of H-bonds of proteins in solution. For 
simplifying the situation, only H-bonds involved in backbone amide H-bonding will be 
discussed. In well-structured region (e.g., α-helices, β-sheets), backbone amide hydrogen 
are protected by intra-molecular H-bonds. This protection dramatically reduces the HDX 
rate constant, kHDX, by as much as 10-6.88 Exchange of these backbone amide hydrogens 
requires temporary H-bond breaking (“opening”) events that are a manifestation of protein 
dynamics. Therefore, by measuring HDX rate it is possible to obtain valuable information 
regarding protein dynamics, which is unavailable through other techniques, such as X-ray 
crystallography. Simply speaking, highly dynamic regions exchange fast, whereas tightly 
folded regions show slow HDX. 
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HDX of backbone amides is usually discussed within the framework of a simple exchange-
in reaction diagram: 
 
Equation 1.5 
Initially, the amide NH is in a “closed” environment with an intact NHOC contact. Due 
to protein thermal fluctuations, such H-bonds will transiently break (or “open”) and then 
subsequently close again. The rate constants of these steps are denoted as kop (opening 
transition) and kcl (closing transition). While a site is “open”, the backbone amide hydrogen 
is labile (Hop) and can be replaced with deuterium from the bulk solution (kch). After the 
exchange, the backbone amide deuterium (Dcl) can be reformed to new H-bond and be 
protected again (Dcl). In a deuterium rich environment, the whole reaction is pushed to the 
right. Similarly, back exchange can take place, e.g. during LC separation of deuterated 
peptides, in a H2O environment encountered during the downstream analysis process.  
From equation 1.5, both Hcl and Hop can be grouped into [Hunexchanged] which represents all 
the unexchanged backbone amide hydrogens in the system.  
𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑 =  𝐻𝑐𝑙 + 𝐻𝑜𝑝 
Equation 1.6 
The population changing of [Hunexchanged] can be described as: 
𝑑[𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑]
𝑑𝑡
= −𝑘𝑐ℎ[𝐻𝑜𝑝] 
Equation 1.7 
The population change of Hop can be described as 
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𝑑[𝐻𝑜𝑝]
𝑑𝑡
= −(𝑘𝑐𝑙 + 𝑘𝑐ℎ)[𝐻𝑜𝑝] + 𝑘𝑜𝑝[𝐻𝑐𝑙] 
Equation 1.8 
During the HDX continuous labeling process, it will always be a period that the generation 
and depletion of Hop are the same and this leaves d[Hop]/dt (equation 1.8) equal to near 0. 
Under these steady-state conditions equation 1.8 can be rearranged to  
(𝑘𝑐𝑙 + 𝑘𝑐ℎ)[𝐻𝑜𝑝] = 𝑘𝑜𝑝[𝐻𝑐𝑙] 
Equation 1.9 
By substituting equation 1.6 into equation 1.9 we find 
(𝑘𝑐𝑙 + 𝑘𝑐ℎ)[𝐻𝑜𝑝] = 𝑘𝑜𝑝(𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑 − 𝐻𝑜𝑝) 
Equation 1.10 
[𝐻𝑜𝑝] =
𝑘𝑜𝑝[𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑]
𝑘𝑐𝑙 + 𝑘𝑐ℎ + 𝑘𝑜𝑝
 
Equation 1.11 
By combining equation 1.7 and equation 1.11, it follows that 
𝑑[𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑]
𝑑𝑡
= −
𝑘𝑐ℎ𝑘𝑜𝑝
𝑘𝑐𝑙 + 𝑘𝑐ℎ + 𝑘𝑜𝑝
[𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑] 
Equation 1.12 
Here we have a new equation that is very close to first order reaction (d[A]/dt =-k[A]).  
Then, it can be further simplified to 
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𝑑[𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑]
𝑑𝑡
= −𝑘𝐻𝐷𝑋[𝐻𝑢𝑛𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑑] 
Equation 1.13 
where 
𝑘𝐻𝐷𝑋 =
𝑘𝑐ℎ𝑘𝑜𝑝
𝑘𝑐𝑙 + 𝑘𝑐ℎ + 𝑘𝑜𝑝
 
Equation 1.14 
kHDX is the rate constant that for backbone amide hydrogen replaced by solvent deuterium. 
In most experimental condition, the protein is more likely to stay folded (closed 
conformation) and kcl is much larger than kop. Therefore, equation 1.14 can be simplified 
to: 
𝑘𝐻𝐷𝑋 =
𝑘𝑐ℎ𝑘𝑜𝑝
𝑘𝑐𝑙 + 𝑘𝑐ℎ
 
Equation 1.15 
The relative magnitude of kcl and kch establishes two limiting HDX scenarios. If kch >> kcl, 
the site will undergo complete HDX after the first opening event. These conditions are 
commonly seen under mildly denaturing conditions. If these slow fluctuations take place 
cooperatively (i.e., if they affect all or many sitest in parallel) two populations can be 
observed: The corresponding mass spectra will show a low mass and a high mass 
contribution (Figure 13).89 As time proceeds, the low mass population (unlabeled protein) 
keeps decreasing while the high mass population increases. This scenario is referred to as 
EX1, and the kHDX equation simplifies to 
𝑘𝐻𝐷𝑋 = 𝑘𝑜𝑝 
Equation 1.16 
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Figure 13. Simulated HDX kinetics under EX2 (A) and EX1 (B) conditions. The numbers 
on the top of each peak denote time points in second. It is rare to see these pure scenarios. 
In reality, EX1 and EX2 are often superimposed, i.e. the protein undergoes fluctuations on 
many different time scales that affect different regions.89 
 
In contrast to EX1, EX2 scenario happens when kch << kcl and this is often seen in native 
environments, which are typical in protein/protein-ligand studies. Under these conditions 
many opening events are required before HDX takes place at any given sites. In mass 
spectrum, EX2 conditions give rise to a single mass distribution that gradually shifts to 
higher m/z as time increases. (Figure 13) Similar to equation 1.11 in EX1, the kHDX 
equation can be rewritten to 
𝑘𝐻𝐷𝑋 = (𝑘𝑜𝑝/𝑘𝑐𝑙)𝑘𝑐ℎ 
Equation 1.17 
Equation 1.12 can be further simplified to  
𝑘𝐻𝐷𝑋 = 𝐾𝑜𝑝𝑘𝑐ℎ 
Equation 1.18 
The hydrogen exchange on peptide backbone amide hydrogen can be catalyzed by H+, OH- 
and water. Each catalyst has its unique intrinsic rate as in  
𝑘𝑐ℎ = 𝑘𝑎𝑐𝑖𝑑[𝐻
+] + 𝑘𝑏𝑎𝑠𝑒[𝑂𝐻
−] + 𝑘𝐻2𝑂[𝐻2𝑂] 
Equation 1.19 
A B 
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Thus, kch is highly pH dependent. A plot of log(kch) vs. pH is V-shaped (Figure 14), and the 
lowest point is around pH 2.5 – 3. This pH range is used as for HDX quenching. At pH 3, 
the exchange halftime has been increased to ~20 minutes. This provides a chance to analyze 
HDX by LC-MS (a typical gradient is around 10~20 minutes), but is still too fast for many 
other experimental methods. 
 
Figure 14. kch of a random coiled poly-alanine chain at 20 °C under various pH.90  
 
Luckily, HDX is also affected by temperature as governed by Arrhenius equation 
𝑘𝑐ℎ = 𝐴𝑒
−
𝐸𝑎
𝑅𝑇 
Equation 1.19 
where Ea is the activation energy, T is the temperature, A is an empirical constant, and R is 
the gas constant (8.314 J mol-1 K-1). As temperature drops, kch decreases exponentially. kch 
can be lowered ~ 10 times by lowering the temperature from 25 to 0°C. Therefore, HDX 
quenching takes place at ~ 0°C and at pH 2.5 - 3.  
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1.4.3 HDX Experiment Design 
For HDX experiments protein samples are diluted into D2O buffer; then aliquots are 
removed and quenched at selected labeling times by lowing the pH to ~3 and cooling to 
0°C (or flash frozen in liquid nitrogen). Afterward, the deuterated protein sample can be 
directly injected into the mass spectrometer, and the mass changes can be observed at the 
intact protein level.91 More detailed information can be derived when incorporating 
enzymatic digestion is incorporated into the workflow. This step requires a specific enzyme 
that is active under quenching condition. Although other types of enzymes are available92, 
porcine pepsin remains to be the gold standard due to its robust nature, low price and well-
established protocols.93 The activity of pepsin is highest at pH 2-4, which matches well 
with the HDX quenching condition. The simplest approach is to mix target protein and 
pepsin in a 1:1 mass ratio for a few minutes. More sophisticated workflows involve pepsin 
immobilization on a column for on-line UPLC experiments that provide highly consistent 
data.94 (Figure 15). The analysis processes are  separated into three successive steps. 1. 
Sample loading: the deuterated sample is injected into the sample loop. 2. Trapping: By 
valve switching, auxiliary solvent manager (ASM) pumps acidified water (pH 2.5, 0.1% 
formic acid in water) through the sample loop, then carries sample into pepsin column 
where the protein is digested. The resulting peptides are trapped in a short (2 cm) C18 
reverse phase trapping column. 3. Injection: binary solvent manager (BSM) pumps an 
acetonitrile/water gradient through the trap column. The trapped peptides are eluted and 
further separated by a downstream analytical C18 column. Finally, HDX data are collected 
by MS. 
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Figure 15. Schematic representation of HDX online digestion module. Lines (red and black) 
shows the solvent flow path. Red lines indicate where deuterated samples are located 
during specific steps. 
 
The modification of HDX instruments does not end here. For increasing digestion 
efficiencies, high pressure on the pepsin column has been proven to be effective.95 The 
integration of an electrochemical module into an HDX online digestion system was 
reported which is capable of reducing disulfide bonds for better digestion coverage.96 The 
full automation of HDX (from sample production to sample injection) makes high 
throughput studies possible and can enhance the efficiency of epitope mapping, drug 
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screening, etc.84  
Several designs of HDX-MS experiments have been proposed for various purposes. These 
methods can be categorized into continuous-labeling and pulsed labeling. As implied by 
the name, continuous labeling means that a protein is incubated in labeling buffer and 
deuterium “continuously” exchanges into the protein. The mass shift is monitored as a 
function of time. Time points cover the range from seconds to hours, sometimes even to 
days. One of the primary usages of continuous labeling is to compare the difference 
between protein states. By interpreting the differences between HDX rates in spatially-
resolved experiments, it may be possible to identify ligand binding sites, allosteric effect 
induced by ligand binding, dynamic changes upon binding, etc. Continuous-labeling is the 
most commonly used HDX-MS strategy in all of them.97  
Another approach is pulsed labeling HDX. In pulsed labeling the protein is often studied 
under non-equilibrium conditions, e.g., during protein folding. Hence one key application 
of pulsed HDX is the detection and characterization of folding intermediates.98 One typical 
experiment design is to transfer denatured proteins into a folding environment quickly. 
Subsequently, while the protein folds, it is exposed to an HDX pulse (in millisecond scale) 
and quenched subsequently with acidification. By controlling the refolding time, transient 
intermediates can be identified on the basis of their unique deuterium uptake properties. It 
is advantageous to design the HDX pulse such that it results in an all-or-nothing scenario: 
e.g., at pD 9, unprotected amides are nearly fully exchanged while marginally protected 
amides (partially folded) only have less than 5% deuteration levels.88 Although finely 
tuning is still required, pulsed labeling HDX remains as a powerful tool in the protein-
folding study arsenal.  
  
1.4.4 Peptide Mapping 
 
Peptide mapping is usually the first step in bottom-up HDX. The traditional peptide 
mapping method is data-dependent acquisition (DDA). During the LC-MS run, MS1 
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survey scans identify the most intense precursor ions and apply MS/MS to identify the 
peptide. This process may have to be repeated several times to identify all ions. Plus, 
optimization of collision energies is needed,99 which can make the process quite time-
consuming. Also, some low abundance peptide may be missed since MS1 survey scans 
only pick up ions that stronger than a certain threshold.  
The development of data independent acquisition (DIA) has tremendously facilitated the 
tedious workflow. The central idea in DIA is all ions are fragmented without precursor 
selection during the LC-MS process. The collision cell in the MS is switched back and 
forth between low and high energy. Therefore, precursors and their fragments are measured 
at the same time. The signal intensity and retention time between each precursor and 
corresponding fragments must be well correlated. Thus, the precursors (peptide) can be 
identified from its paired fragments with the help of computer software/algorithms.100 
Therefore, the peptide mapping processing is greatly simplified and can sometimes be 
performed in a single run.  
 
1.4.5 Data Analysis in HDX-MS 
 
Once HDX data are obtained, the question becomes how to extract the protein dynamic 
behavior from the measured isotope distributions. Here we are going to take bottom-up 
HDX-MS as an example to explain the general method of data analysis.  
For a typical HDX experiment, it is impossible to completely avoid back exchange, 
especially when on-line digestion and HPLC/UPLC separation are applied. For correcting 
the back exchange, two types of control samples need to be prepared: 1st, m0: a protein 
sample that is exposed to deuterated buffer with minimum time under quenched condition. 
2nd, m100: a protein sample that has attained maximum deuteration. The corrected 
deuteration percentage (Dt) at each specific time point t can then be calculated from the 
following equation:101 
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𝐷𝑡 =
𝑚𝑡 − 𝑚0
𝑚100 − 𝑚0
× 100% 
Equation 1.20 
where mt is the centroid mass of deuterated peptide at the particular time point. An HDX 
uptake curve then can be plotted as Dt vs. time.  
In principle, kHDX (discussed in section 1.4.2), the rate constant of HDX, can be acquired 
by fitting the HDX uptake curve. However, each amide has its own rate constant which 
generally results in multi-exponential kinetics. For simplifying the analysis, the amide 
hydrogens are often grouped into three categories: fast, intermediate and slow. A suitable 
fitting equation under such conditions is shown as the following:101 
D𝑡 = N1(1 − e
−k1t) + N2(1 − e
−k2t) +  N3(1 − e
−k3t) 
Equation 1.21 
where N1 and N2 and N3 are the numbers of fast, intermediate and slow exchanging amide 
hydrogens, respectively; and k1, k2, and k3 are the corresponding HDX rate constants. Since 
k3 usually is very close to 0, that brings the 3rd term in the equation 1.24 also near 0. 
Therefore, the equation is often further simplified to 
D𝑡 = N1(1 − e
−k1t) +  N2(1 − e
−k2t) 
Equation 1.22 
This two components equation usually works reasonable well with most EX2 HDX-MS 
data. For EX1 data, different population need to be separated first before fitting with 
equation 1.24 or 1.25. 
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1.4.6 Applications of HDX 
 
The application of HDX covers various fields. One of the major aspects is to investigate 
protein-ligand interactions. The interaction between protein and ligand is the trigger of 
plenty of biological activities which are important for enzymatic catalysis, the function of 
the immune system, transmembrane ion transport, etc. The protein-ligand interactions are 
usually non-covalent and reversible, as expressed in  
 
 
Equation 1.23 
where P is the protein; L is the ligand; PL is the protein-ligand complex. The dissociation 
constant (Kd) equals to [P][L]/[PL]. In most case, binding of a ligand (e.g., a drug molecule) 
decreases the deuteration rate around the ligand binding region, which implies the ligand-
protein complex are more folded/protected.19,102 However, in some scenarios, ligand 
binding can increase the hydrogen-deuterium rate. The oxygenation of hemoglobin is such 
a case: the HDX rate is increased at the heterodimers interface while oxygen binds.103 
The discovery of small molecule therapeutics can also benefit from using HDX to monitor 
protein-ligand interaction. On G protein-coupled receptors (GPCRs), HDX-MS has 
emerged to be one important tool to explore its conformational and allosteric changes upon 
ligand/drug binding. In one study, HDX was used to identify ligand-binding loops on the 
β2-adrenergic receptor, that where not resolved in crystal structures.104 HDX can also be 
used to direct the development of therapeutic antibodies by mapping epitopes upon protein 
complexes.105,106 The application of HDX-MS can be further used to test protein 
therapeutics. One example involves insulin analogs that were probed by HDX for their 
pharmacokinetics and stability.107 
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1.5 Molecular Dynamics (MD) Simulations 
 
As previously discussed, proteins are in constant movement, i.e., they undergo thermal 
motions that are coupled to the dynamics of the surrounding solvent.108 HDX methods 
represent an experimental tool to probe these protein dynamics. Computer simulations (in 
particular, MD methods) are a valuable tool to directly visualize protein movements and 
conformational changes from an atomistic perspective. One significant advantage of MD 
simulation is that it can reveal movements of molecules between the start and the end of a 
process/transformation. This is a vital complement to many other experimental methods 
since most time only the start and the end of an experiment are observed and analyzed.  
 
1.5.1 Background of MD Simulations 
 
In a perfect world with unlimited resource and time, the behavior and trajectories of all 
molecules could be predicted ab initio by the time-dependent Schrödinger equation. 
However, realistically, one has to make approximations to be able to obtain simulation 
results in reasonable time. MD simulations represent a computational technique that has a 
relatively low computational cost. MD uses Newton’s law to calculate the motion of atoms: 
𝐹 = 𝑚𝑎 
Equation 1.24 
The forces applied to the atoms are provided by the potential energy calculated from force 
fields. Force fields are an assembly of empirical parameters that define interactions 
between atoms.109,110 These parameters can be classed into two groups: bonded and non-
bonded interactions. Bonded interactions describe the behavior of covalent bonds, 
including stretching and bending, torsion potentials of bond rotation, etc. Nonbonded 
interactions are described as Lennard-Jones and Coulombic electrostatic potentials. 
Nonbonded interactions are calculated between any pair of atoms. If two atoms are 
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separated by a large distance, these nonbonded interactions become rather weak. For 
reducing computational cost, a cut-off value is commonly used for Lennard-Jones potential 
since it decays very fast. The case is more complicated for Coulombic interactions 
especially when periodic boundary conditions (see below) are applied. This is because the 
Coulomb potential decays much slower than the Lennard-Jone potential at long range. A 
simple Coulomb cut-off would induce severe atifacts.111 Therefore, the Partical-Mesh-
Ewald (PME) algorithm is used to calculate Coulombic interactions beyond the cut-off 
distance at relatively low computational cost112, allowing better efficiency and accuracy in 
large systems, such as proteins in solution.  
Periodic boundary conditions (PBC) allow simulating quasi-infinite systems, thereby 
eliminating surface artifact that would otherwise be encountered in bulk solution studies.112 
The idea of PBCs is that the actual simulation box is surrounded with identical copies of 
itself in all directions. If an object leaves the box on one side, it will re-enter from the other 
side with the same speed and direction (Figure 16). In this way, an extensive, homogeneous 
system can be simulated with no boundaries in MD. 
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Figure 16 Schematic of periodic boundary conditions (PBC) 
MD is an excellent tool for many applications, but it cannot simulate the formation and 
breaking of covalent bonds. That precludes the application of MD techniques to simulating 
chemical reactions. Despite this limitation, MD techniques allow simulations on many 
interesting bio-macromolecules on nanosecond to millisecond time scales, which is nearly 
impossible for quantum or DFT methods. 
A number of MD packages are available. Some have been commercialized, such as 
Abalone II; but there are also quite a few free/open source MD platforms. Gromacs is one 
of them. It is versatile, easy to use, and can be modified to suit the user’s needs. In the rest 
of section 1.5, we will take Gromacs as an example to discuss the steps of a typical MD 
simulation. 
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1.5.2 Steps to Perform a MD Simulation 
 
The first step of a MD simulation is to introduce the starting structure into the system. A 
static “picture” of the molecule which describes all atoms and their interactions is needed 
for this step; the “picture” is named as topology. In Gromacs, the topology file is generated 
by the program pdb2gmx. pdb2gmx reads data from protein’s pdb file and adds all the 
missing hydrogen atoms. pdb2gmx allows the user to select the forcefield, water model, 
protonation sites, etc. Once finished, pdb2gmx puts the molecule in a simulation box and 
the box with user-defined interactions.  
After protein coordinates are introduced into the MD simulation, water and ions can be 
added into the box. This allows the protein to be simulated in a solvated environment and 
the input of ions makes the environment closer to the physiological state. These newly 
added molecules may be placed into unrealistic positions and could generate large forces 
that might crash the system. For this reason, it is necessary to perform an energy 
minimization procedure to “relax” the system. Energy minimization allows all atoms to 
move by a small distance in the direction that lowers the potential energy. 
In the energy minimization step, solvent (water and ions) is optimized with itself, but not 
necessarily with the protein. Therefore, further action is needed to equilibrate the solvent 
around the protein. The first phase of the equilibration step is conducted under constant 
temperature, volume and number of particles, also known as NVT. The initial velocities of 
all atoms can be assigned randomly from a Maxwell-Boltzmann distribution at the desired 
temperature. NVT equilibration stabilizes the system around the required temperature. 
After that, the pressure/density of the system can be equilibrated through an NPT step, 
which has the constant temperature, pressure, and the number of particles. After these 
equilibration steps are finished, the system is ready for the actual simulation run.  
The MD simulation runs in time steps: the system will move with the assigned velocity 
without disturbance for one time step (typically 2 fs). The new coordinates of particles are 
recorded in the trajectory files. Potential energy and velocities of particles are then 
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recalculated. With the new velocities and coordinates, the system runs for another time step 
and repeats until the whole simulation finishes.  
 
1.5.3 Trajectory Analysis 
 
Once the MD simulation finishes, the trajectory files are ready to be analyzed. The most 
straightforward tool is to compare the protein structure before and after the MD simulation. 
The standard way to do this is to calculate the root mean square deviations (RMSD) 
between protein structures. RMSD reports by how much a structure deviate from a 
reference structure. The equation is 
𝑅𝑀𝑆𝐷 =  √
1
𝑁
∑ 𝐷𝑖
2
𝑁
𝑖=1
 
Equation 1.25 
where Di is the distance between atom i and its reference position; N is the number of atoms. 
The higher the RMSD, the larger the difference between structures.  
It is also interesting to track the protein’s dynamics during the simulation. In MD 
simulation the fluctuation of atoms or amino acid residues can be measured by root mean 
square fluctuation (RMSF). RMSF is very similar to RMSD except the position deviation 
is averaged over time. Also, RMSD is generally referred to entire or segment of the protein; 
RMSF is more specific for single residue or atom. The Equation of RMSF is shown as the 
following  
𝑅𝑀𝑆F =  √
1
t
∑ 𝑑𝑖
2
𝑡
𝑖=1
 
Equation 1.26 
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where t is the time, d is the distance between atom i and its reference at the different time 
point. For protein, normally only RMSF of backbones are calculated since side chains are 
way more fluctuating even in tightly packed secondary structure.  
Since all the atoms/molecules coordinates of all the time points are stored in the trajectory 
file, a movie of molecular movement can be made to present the protein conformational 
change or coordinating with its ligand.113 This makes data presented more attractive and 
straightforward. The analysis of MD data is unrestricted. From MD data, one can analyze 
the center of mass, radius of gyration, distance/bond/dihedral angles between two particles, 
H-bond formation to explore the changes in the system.  
Recently, with the help of state of the art supercomputers, the time scale of MD has been 
pushed into the ms scale, which brings the MD simulation closer to experimental 
conditions.114 MD has contributed tremendously to various fields including protein-
folding115, surface chemistry116, instrument development117, and will continue to expand 
into new application areas.  
 
 
1.6 Scope of Thesis 
 
HDX-MS is an ideal tool to study dynamic features of proteins. HDX rates reflects whether 
the local region is protected and folded. MD simulation is another technique that can 
explore protein dynamics. HDX-MS and MD simulations complement each other in time 
scales and resolution: HDX visualizes opening/closing reactions that take place within 
microseconds to minutes, and information is obtained at the level of peptides; MD 
simulations probe the behavior of proteins on a ns to ms time scale, and information is 
obtained for each atom in the system. 
The objective of this work is to investigate protein dynamics of three different systems. 
Different aspects of proteins are explored: protein folding, protein-ligand interactions, and 
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allosteric effects. While these efforts primarily provide very fundamental information, they 
could ultimately help the biotechnological industry, and assist in the development of new 
pharmaceuticals.   
Chapter 2 was inspired by previous work done by Hedges118 to explore how proteins 
interact with gas/liquid interfaces (in the form of bubbles). While the work of Hedges 
focused on proteins in ESI droplets, our aim is to explore the behavior in bulk solution, 
e.g., in a bioreactor. This Chapter used HDX-MS to probe the protein dynamics of a model 
protein (myoglobin) in the presence of N2 bubbles. The data suggest that proteins on the 
interface adopt a globally unfolded, long-lived state that can proceed in two directions: 
refolding to the native state or aggregation. A simple computational model was devised to 
quantitatively reproduce the experimental kinetics. 
Chapter 3 continues to use HDX-MS to explore protein dynamic properties upon ligand 
binding. The OPG/RANKL/HS system is crucial for regulating bone formation. HDX-MS 
revealed HS-binding site on OPG; also, RANKL induced stabilization of OPG was 
observed. A schematic mechanism is proposed based on the HDX data to explain how the 
HS-induced stabilization effect could promote the binding affinity between OPG and 
RANKL. 
Finally, Chapter 4 combines MD simulations and HDX-MS to investigate allosteric effects 
in a protein-ligand system. The S100A11-Annexin A1 complex is studied in this project. 
Both HDX-MS and MD data shows the loss of Ca2+ made the binding site more dynamics. 
However, our data suggest the enhanced dynamics is not the actual trigger of the allosteric 
effects induced by Ca2+ binding. Instead, Ca2+ appears to block the signals that emanate 
from a remote agitator. This blocking mechanism challenges existing paradigms related to 
the mechanism of allosteric regulation in proteins. 
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Chapter 2: Protein Structural Dynamics at the Gas/Water 
Interface Examined by Hydrogen Exchange Mass 
Spectrometry 
 
2.1  Introduction 
 
Under physiological conditions most globular proteins adopt a highly ordered 
conformation, comprising a hydrophobic core and a hydrophilic exterior.1 This native state 
can be destabilized by exposure to extremes of pH, high or low temperature, and 
denaturants such as urea.2-4 These physical and chemical agents can result in various 
degrees of unfolding, from semi-structured molten globules all the way to the random coil 
state.5-7 Non-native conformers formed in this way are often prone to aggregation.8,9 
Proteins have become a valuable commodity – not only as enzymes for industrial processes 
but also as vaccines and therapeutic agents. Protein drugs such as monoclonal antibodies 
and antibody-drug conjugates have a rapidly growing market share.10,11 The formulation, 
processing, and packaging of these proteins may induce various degradation processes.12,13 
In other words, structural changes and/or aggregation may take place even if the proteins 
are never exposed to any of the “classical” denaturing agents mentioned above.14-16 
Especially for protein drugs these issues are of concern because degradation may affect 
their efficacy and immunogenicity.16 Early investigations considered shear stress 
experienced during pumping and stirring to be a major cause of degradation.17 Recent 
studies found shear effects on proteins to be negligible,13,18-20 although shear can certainly 
damage protein-producing cells in stirred-tank reactors.11,21,22 
 It has now been established that a key factor associated with the degradation of proteins 
during processing is the presence of gas/water interfaces in the form of bubbles or 
foam.14,15,23-27 Proteins exhibit a high affinity for these interfaces. Protein-induced foaming 
52 
 
in bioreactors can lead to overflow and other problems during large-scale industrial 
operations.28 On the other hand, foam stabilization via protein adsorption is beneficial for 
many food and beverage formulations, exemplified by the frothy appearance of whisked 
egg-white and the foaming of beer.25,29 The texture and shelf life of aerated food products 
greatly depends on the capability of proteins to prevent the coalescence of gas bubbles.30 
Similar considerations apply to the interaction of proteins with oil/water interfaces, a factor 
that is important for the stabilization of emulsions such as milk. 31 
The affinity of proteins for gas/water interfaces is related to the amphiphilic nature of the 
polypeptide chains. In a manner that is reminiscent of low molecular-weight surfactants, 
hydrophobic residues tend to orient themselves towards the gas phase, whereas hydrophilic 
moieties will remain solvated by water. The tendency of previously buried hydrophobic 
sites to maximize interactions with the gaseous side of the interface often forces adsorbed 
proteins to adopt non-native conformations14,25,28,29 that readily aggregate.14,15,23-27 
Despite the considerable interest in surface denaturation phenomena, the exact nature of 
protein structure and dynamics at gas/water interfaces remains poorly understood. Previous 
work in this area employed probes such as CD, fluorescence, or FTIR spectroscopy, light 
and small-angle X-ray scattering, as well as surface tension measurements.14,15,25,31 Protein 
losses due to aggregation have been quantified by UV-Vis absorbance measurements14,27 
and radioactivity assays.26  
Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) has emerged as a versatile 
tool for examining protein structural features and conformational fluctuations under a wide 
range of conditions. 32-40 This technique relies on the fact that exposure of a protein to D2O 
will induce the replacement of amide backbone hydrogens with deuterium.41-43 Limited 
proteolysis of the labeled protein with subsequent LC separation and mass analysis of the 
resulting peptides allows HDX kinetics to be measured in a spatially-resolved manner. 
In near-neutral solution unstructured protein regions undergo rapid HDX with a 
“chemical” rate constant kch that is on the order of 650 min-1.43 Deuteration in folded 
segments proceeds much more slowly, mediated by structural fluctuations that transiently 
disrupt N-H....O=C hydrogen bonds while providing solvent access to amide backbone 
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sites.44 These thermally activated dynamics cause each protein to constantly cycle through 
all of its Boltzmann-accessible conformations.44 Although the steady-state concentration 
of most excited conformers is low, the measured HDX behavior is largely governed by 
these conformational dynamics. The opening and closing rate constants associated with 
HDX-relevant structural fluctuations are referred to as kop and kcl, respectively. Two 
different regimes can be distinguished. Under most conditions the open states have a 
relatively short lifetime (kcl  >> kch), such that numerous opening/closing events are 
required before all NH groups associated with a given structural transition are deuterated. 
This so-called EX2 limit is recognizable in HDX/MS as a continuous shift of the peak 
envelopes to higher mass, with an overall deuteration rate constant 45-48 
    kHDX = kop / kcl  kch  
Equation 2.1 
Alternatively, proteins may undergo cooperative dynamics where the open state is quite 
long-lived (kcl  << kch) such that complete deuteration of the corresponding NH sites will 
take place during the first opening event. These “EX1” dynamics give rise to bimodal 
distributions where the relative intensity of the high mass component increases with time, 
and where45-48 
 kHDX = kop  
Equation 2.2  
Using met-myoglobin (Mb) as model system, the current work employs HDX/MS to 
examine protein structure and dynamics at the gas/water interface. Mb is an archetypical 
globular protein49 with a native state that comprises eight helices. Most nonpolar side 
chains are sequestered in a well-developed hydrophobic core. The protein binds heme in a 
nonpolar pocket, with Fe3+ ligation by the proximal His93. The choice of Mb for the 
experiments of this study is based on previous work that revealed Mb to be highly 
susceptible to the presence of gas/water interfaces.27 By conducting comparative 
experiments on Mb solutions with and without N2 sparging we obtain detailed insights into 
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the mechanism by which gas/water interfaces promote unfolding and aggregation. We 
develop a kinetic model that is capable of quantitatively describing the experimentally 
observed interplay between aggregation and EX1/EX2 conformational fluctuations. It 
appears that this study marks the first use of HDX/MS as a tool for exploring surface 
denaturation effects. 
 
2.2 Methods 
 
2.2.1 Materials 
 
Equine skeletal muscle Mb was purchased from Sigma (St. Louis, MO). HCl, Na2HPO4 
and NaH2PO4 were obtained from Caledon (Georgetown, ON, Canada). D2O was procured 
from Aldrich (St. Louis, MO). LC-MS grade H2O was purchased from Optima (Fair Lawn, 
NJ). All protein solutions were prepared in 50 mM phosphate buffer. pH values were 
measured using a Fisher (Waltham, MA) AB15 pH meter. All experiments were carried 
out at a pH meter reading of 7.1, without correction for isotope effects.  
 
2.1.1 Gas/Water Interface Exposure and HDX 
 
200 μL aliquots of 5 μM Mb in 90% D2O were placed in Eppendorf tubes. N2 was bubbled 
through these solutions at 5 L h-1 using a syringe needle with an inner diameter of 0.8 mm. 
This procedure was carried out at room temperature (23  1 ˚C). After various deuteration 
time periods ranging from 1 to 20 minutes the gas flow was stopped. Insoluble aggregates 
formed during this treatment were removed by centrifugation at 10,000 rpm for 30 s. HDX 
was quenched by adding HCl to the supernatant, resulting in a pH meter reading of 2.4. 
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Subsequently, samples were flash frozen in liquid nitrogen until further analysis. Times 
reported in the text above refer to the bubble-exposure period, not including of the ~60 s 
required for centrifugation, centrifuge deceleration, and sample handling prior to freezing. 
Measurements for quantifying protein loss due to aggregation were conducted using non-
deuterated buffer solutions. Control samples for all measurements were prepared exactly 
as described above, but without N2 bubbling. 
 
2.1.2 Mass Spectrometry 
 
Frozen deuterated samples were rapidly thawed to ~0 ˚C. Intact protein HDX/MS 
employed a reversed-phase column for desalting (BEH C4, 1.7 µm, 2.1  50 mm, Waters, 
Milford, MA) with a 10 min water/acetonitrile gradient at 200 µL min-1 in the presence of 
0.1% formic acid. The sample loop had a 20 µL volume and the amount of Mb per injection 
was 100 pmol. The column, injector and solvent lines were kept in ice for maintaining a 
temperature close to 0 ˚C to minimize H/D back exchange. The column outlet was 
connected to a Waters Synapt HDMS quadrupole time-of-flight mass spectrometer. Intact 
protein analyses focused on the 18+ charge state which exhibited the highest S/N ratio.  
Peptide-level deuteration measurements were conducted using a nanoACQUITY UPLC 
with HDX technology (Waters)50 Online digestion was performed using a 2.1 mm  30 
mm POROS pepsin column (Life Technologies/Applied Biosystems, Carlsbad, CA) at 15 
˚C. A 20 min water/acetonitrile (0.1% formic acid) gradient was used for desalting and 
peptide separation at 0 ˚C. Peptide mass analysis was performed on a Waters Synapt G2 
mass spectrometer. The identity of each peptide was confirmed by tandem MS on non-
deuterated samples based on the known Mb sequence.49 Peptide mass spectra were 
recorded with an electrospray capillary voltage of +2.8 kV, 30 V cone voltage and a 
desolvation temperature of 250 ˚C. Mass calibration was performed using 2 µg µL-1 NaI in 
50:50 water: isopropanol at a capillary voltage of 1.2 kV. Deuteration percentages were 
calculated as (m – m0)/(m100 – m0). Zero-time-point controls (m0) were prepared by 
exposing the protein to 90% D2O buffer under quench conditions. Fully exchanged control 
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samples (m100) were prepared by incubating Mb in 90% D2O at pD 2.4 / 37 ˚C for 12 h. All 
experiments were carried out in triplicate. Error bars represent standard deviations.  
 
2.2  Results and Discussion 
 
2.2.1 Protein Aggregation in the Presence of Gas Bubbles 
 
Sparging of Mb solutions with N2 bubbles results in the formation of insoluble aggregates. 
The assay used for examining this process involves precipitate removal by centrifugation, 
followed by LC/MS analysis of the supernatant. The loss of soluble protein in the presence 
of N2 bubbles can be approximated as an exponential decay with an apparent rate constant 
of kagg = 0.054 min
-1. In contrast, the protein concentration in bubble-free control samples 
remains constant (Figure 1). 
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Figure 1. Relative amount of soluble protein in the presence and absence of N2 bubbles, 
as monitored by ESI-MS signal intensity measurements. Protein loss in the presence of 
bubbles is attributed to aggregation. The red curve is an exponential fit with an apparent 
rate constant of 0.054 min-1. 
 
The occurrence of Mb aggregation under the conditions of our experiments is consistent 
with earlier observations on other proteins.15,23-27 In particular, it has been noted14 that 
sparging is characterized by a nascent interface area that continuously renews itself. These 
conditions are much more effective in causing aggregation than the “static” surface of 
regular protein samples.14 A likely explanation for this difference is that the surface of 
regular samples is decorated with a metastable thin film of adsorbed protein. This film 
prevents bulk solution proteins from coming into direct contact with the air/water interface. 
Sparging, on the other hand, continuously produces bare air/water interface that will readily 
adsorb proteins. Bubbles rise until they burst, leaving previously adsorbed proteins in non-
native conformations that are prone to aggregation. Alternatively, aggregation may begin 
already while proteins are still in contact with the bubble surface. 
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2.2.2 Intact Protein HDX/MS 
 
Mb conformational dynamics in the absence and in the presence of N2 bubbles were probed 
using HDX/MS. As a first step the Mb behavior was monitored at the intact protein level. 
In agreement with previous reports,40,51 bubble-free control samples display EX2 kinetics 
with mass distributions that gradually shift to higher m/z, (Figure 2A). A drastically 
different behavior was observed in the presence of N2 bubbles, with spectra that are 
bimodal for t > 2 min (Figure 2B). The decreasing relative intensity of the low mass 
component and the increasing intensity of the high mass component represent the hallmark 
of EX1 exchange.45,46 In addition, a gradual shift of the low mass component is apparent 
in Figure 2B which reveals that the protein also undergoes EX2 deuteration. The spectra in 
Figure 2B are normalized such that each time point has the same integrated area. This 
representation is helpful for recognizing the occurrence of combined EX1/EX2 dynamics 
45 in the sparged samples, but it masks the ongoing loss of soluble protein due to 
aggregation (as discussed above, Figure 1). A more realistic view of the protein behavior 
is provided in Figure 2C, where the HDX mass spectra of the sparged samples are displayed 
using actual signal intensities such that aggregation effects become easily recognizable. 
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Figure 2. Mb mass spectra recorded at different HDX time points in the absence (A) and 
in the presence (B), (C) of N2 bubbles. The data shown here correspond to the 18+ 
charge state. Time-dependent shifts in peak maxima (EX2 behavior) are highlighted in 
panels A, B using arrows. In addition, for panel B time-dependent changes in the relative 
intensity of high mass vs. low mass component (EX1 behavior) are emphasized. The 
spectra in (B) were normalized such that each time point represents the same integrated 
intensity. (C) The same data as in panel B, but with actual intensities that reflect the time-
dependent decrease in overall signal due to aggregation. Unresolved cation adducts are 
highlighted for the t = 0 spectrum in panel A. 
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By tracking the low mass peak maxima in Figure 2 it is found that the EX2 kinetics without 
and with bubble sparging are quite similar. Both EX2 deuteration profiles approach a 
maximum level around 55%, with kHDX
EX2 values of 0.79 min-1 and 0.56 min-1, respectively 
(Figure 3A). For EX1 analyses one has to determine the signal intensities associated with 
the high mass and the low mass components, i.e., Ihigh and Ilow. The kinetics can then be 
determined by using the relationship52 
highlow
high
II
I
nDeuteratioEX

1  
Equation 2.3 
Figure 2 reveals the occurrence of peak tailing due to cation adduction.53 This type of 
artifact is common in intact protein HDX/MS.54 Cation adduction is observed regardless 
of experimental conditions (see for example Figure 2A). Overlap of adduct signals with 
the high mass EX1 component renders the data analysis somewhat difficult. The EX1 data 
of Figure 2B were therefore analyzed in a semi-quantitative fashion by assuming that both 
components can be described using the peak shape of the t = 0 profiles, subject to the 
appropriate mass shifts. On the basis of equation 2.3 these data were then converted to an 
EX1 profile (Figure 3B). These data can be described by an exponential curve with kHDX
EX1 
= 0.084 min-1. The scatter in the experimental data points is attributed to the challenges 
outlined above. 
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Figure 3. Intact Mb HDX profiles extracted from the data of Figure 2. (A) EX2 kinetics 
in the absence and in the presence of N2 bubbles. Curves are exponential fits with 
kHDXEX2 = 0.79 min-1 and 0.56 min-1, respectively. The “red” profile shows fewer data 
points because the EX2 component becomes indiscernible for t > 10 min in the presence 
of N2 bubbles. (B) EX1 kinetics observed in the presence of bubbles. The exponential fit 
has kHDXEX1 = 0.084 min-1. 
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Summarizing the intact protein data of Figures 1-3 it can be stated that the exposure of Mb 
to N2 bubbles results in a combination of EX1 and EX2 conformational dynamics, in 
conjunction with aggregation. Without sparging only EX2 behavior is observed. 
 
2.2.3 Proteolytic Digestion HDX/MS 
 
For gaining additional insights into the Mb behavior in the presence of N2 bubbles we 
analyzed the HDX/MS behavior of the protein at the peptide level. For short peptides it is 
difficult to differentiate between EX1 and EX2 behavior. Our attention was therefore 
focused on relatively large segments that comprised 15 to 35 residues. In the presence of 
N2 bubbles all of these peptides display bimodal mass distributions, as exemplified in 
Figure 4. This finding implies the EX1 structural dynamics correspond to global 
opening/closing transitions that affect the entire Mb structure, not just individual parts of 
the protein. Gaussian decomposition allows a determination of EX1 kinetic profiles on the 
basis of equation 2.3. The resulting kinetic plots confirm that the EX1 dynamics for all 
peptides are very similar, as would be expected for global conformational fluctuations 
(Figure 5A). Global analysis of this data set results in kHDX
EX1 = 0.089 min-1, close to the 
value obtained from the intact protein data of Figure 3B. 
By tracking the maxima of the low mass Gaussian component for each peptide it is possible 
to monitor the EX2 kinetics of the protein. Data for three representative segments are 
depicted in Figure 5B-D (residues 1-29, 70-103, and 138-151). The EX2 kinetics for all 
three peptides are well described by kHDX
EX2 values on the order of 0.5 min-1, both in the 
presence and in the absence of N2 sparging (see caption of Figure 5 for details). 
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Figure 4.  HDX mass spectra of three representative Mb peptides recorded at different 
time points in the presence of N2 bubbles. EX1/EX2 kinetics were analyzed using two-
component Gaussian decompositions. The analysis was performed using Microsoft Excel 
Solver for global fitting that required the peak position and fwhm to be the same for the 
high mass component of each peptide for all time points. 
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Figure 5. (A) EX1 kinetics of Mb peptic fragments in the presence of N2 bubbles. The 
solid line represents a global fit to the combined data, with kHDX
EX1 = 0.089 min-1. Intact 
protein data are included as well. Panels B-D show a comparison of EX2 kinetic profiles 
recorded in the absence and in the presence of N2 bubbles. (B) Residues 1-29, kHDX
EX2 = 
0.41 and 0.42 min-1; (C) residues 70-103, kHDX
EX2 = 0.57 and 0.88 min-1; (D) residues 
138-151, kHDX
EX2 = 0.36 and 0.71 min-1. 
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2.2.4 Mb at the Gas/Water Interface: A Simple Kinetic Model 
 
The data presented in the preceding sections demonstrate that Mb in the presence of N2 
bubbles undergoes both EX2 and EX1 fluctuations, as well as aggregation. We will now 
devise a model that is capable of describing these processes in a quantitative fashion. It is 
not our aim to provide an atomistic framework, rather we strive to come up with the 
simplest possible description of the Mb behavior.  
In bubble-free solution ~55% of backbone amides are involved in rapid sub-global 
fluctuations that give rise to EX2 kinetics (Figure 3A). Earlier work has revealed that the 
corresponding sites are located in the N-terminal region of helix A, as well as helices B, C, 
D, and the C-terminal half of helix H.40 We make the simplifying assumption that all of 
these sites participate in a single type of opening/closing transition, corresponding to 
“foldon” fluctuations44 between a semi-unfolded species and the native state. These 
dynamics may be described using the notation OC  CC, where the first letter designates 
the status (“O” open, or “C” closed) of the 55% of amides that participates in the EX2 
dynamics. The second letter signifies the residual 45% that do not participate in the EX2 
dynamics. 
Upon exposure to gas bubbles the EX2 kinetics do not change very much (Figure 3A). 
However, N2 sparging gives rise to additional EX1 conformational transitions that expose 
all amides to the solvent (Figure 5A), implying the involvement of surface-adsorbed 
conformers that are globally unfolded (“OO”). Inclusion of this species extends the model 
to OC  CC  OO. As a final step, aggregation has to be considered. The lack of protein 
loss in bubble-free solution suggests that neither OC nor CC are particularly susceptible to 
aggregation. This leaves OO as the most likely aggregation-prone species. OO can either 
refold to CC, or it can form aggregates. This kinetic competition can be incorporated by 
modifying the model to 
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OC  CC  OO  aggregated  (see Figure 6A for a complete description that includes 
rate constants). A cartoon representation of the four kinetic species is provided in Figure 
6B, emphasizing their different degrees of “openness”, as well as the interaction of 
nonpolar residues (orange) with the gas/water interface14,15,23-29 in the OO state. 
 
 
Figure 6. Kinetic model of the protein dynamics in the presence of N2 bubbles. Backbone 
amides are conceptually divided into two groups, each of which can either be open (“O”) 
or closed (“C”). (A) The CC native state undergoes EX2 fluctuations to the semi-
unfolded conformer OC. Alternatively, CC can undergo EX1 fluctuations to the fully 
unfolded species OO which is adsorbed to the gas/water interface. The latter can either 
refold or aggregate. (B) The same model as in panel A, with cartoon representations for 
each of the four species. Orange color represents hydrophobic residues. (C) Free energy 
profile of the protein. Numbers indicate G (in kJ mol-1) relative to the CC native state. 
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The appropriateness of the model can be scrutinized by testing whether it is capable of 
reproducing the experimental HDX and aggregation kinetics. We previously developed a 
procedure for simulating deuteration processes that are associated with the interconversion 
of different conformers.45 That method iteratively tracks the behavior of a population of bit 
strings (proteins), where each position (backbone amide site) is occupied by either 0 
(hydrogen) or 1 (deuterium). Opening/closing dynamics of user-defined protein regions 
take place with probabilities governed by the corresponding kop and kcl values. Open sites 
undergo 0  1 conversion (deuteration) with a probability that depends on kch. The mass 
shift distribution of the population is analyzed at selected time points by adding the number 
of 1s in each of the proteins. It was already demonstrated that a OC  CC  OO model 
is capable of describing the simultaneous occurrence of EX1 and EX2 kinetics (see Figure 
5 in ref. 45). For the current work we extend this framework by incorporating an aggregation 
step, as envisioned in Figure 6. This is achieved by implementing a reaction path that 
removes OO with a probability W that is given by 
W = 1 – exp(-kagg  ) 
Equation 2.4 
where kagg is the aggregation rate constant and  is the iteration time step.45 
Given the minimalist nature of the model, a number of simplifications are required. We 
assume that chemical exchange proceeds with kch = 650 min
-1 at all sites, representing the 
amino acid-averaged value at neutral pH.43 For EX2 deuteration (kcl >> kch) it is assumed 
that kcl
EX2 = 6500 min-1. Conversely, for EX1 kinetics (kcl << kch) we use kcl
EX1 = 65 min-1. 
The experimentally measured kHDX
EX2 = 0.56 min-1 (Figure 3A) then corresponds to kop
EX2 
= 5.6 min-1, as dictated by equation 2.1. For a “pure” EX1 scenario the fitted rate constant 
of Figure 3B would suggest that kop
EX1 = kHDX
EX1 = 0.084 min-1 (equation 2.2). However, 
the kinetic competition between kcl
EX1 and kagg renders equation 2.2 inadequate for the 
reaction scheme of Figure 6A. To address this point, we empirically settled on a slightly 
higher value of kop
EX1 = 0.12 min-1. Aggregation of OO was approximated as a first-order 
process with kagg = 44 min
-1. Figure 7 demonstrates that this choice of parameters results 
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in excellent agreement between the experimental data (red) and the simulated kinetics 
(blue). 
 
Figure 7.  Simulation results, using the model of Figure 6 for describing the HDX and 
aggregation kinetics. (A) Intact protein mass shift distributions, (B) aggregation kinetics, 
(C) EX2 kinetics, (D) EX1 kinetics. Simulation results in panels B-D are displayed in 
blue, whereas experimental data (from Figures 1, 3A, 5A) are shown in red. Simulations 
were conducted using the method of ref. 45 for 5000 proteins with rate constants as 
defined in the text. 
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The agreement between modeled and experimental kinetics (Figure 7) suggests that the 
framework of Figure 6 provides a reasonable approximation of the protein dynamics in the 
presence of N2 bubbles. We do not claim that this model is unique; alternative scenarios 
such as CC  OC  OO  aggregated might fit the data equally well. However, from 
our experiments there is no evidence that OC is an obligatory intermediate for the 
formation of OO. It was therefore decided to put forward the model of Figure 6, which 
does not involve a direct OC  OO transition. 
 
2.2.5 Free Energy Landscape of Mb at the Gas/Water Interface 
 
Having determined the rate constants associated with the model, one can proceed to outline 
the energy landscape of the protein in the presence of N2 bubbles (summarized in Figure 
6C). The free energy of OC and OO relative to the CC ground state is given by44,45 
   
cl
op
k
k
RTG ln  
Equation 2.5 
yielding values of 18 and 16 kJ mol-1, respectively. At first sight, it might seem surprising 
that OC and OO possess almost the same free energy, considering that they represent very 
different degrees of unfolding. This apparent contradiction is resolved when considering 
that the globally unfolded conformer OO is stabilized by adsorption to the gas/water 
interface. 
For estimating the height of the activation barriers (G#) that separate the protein 
conformers we use the Kramers equation55-59 
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Equation 2.6 
with a pre-exponential factor of C  6  109 min-1.60 The resulting activation barrier heights 
for OC  CC and CC  OO are 52 kJ mol-1 and 61 kJ mol-1, respectively. These numbers 
suggest that the transition state for global unfolding is much more unfavorable than that 
leading to the semi-unfolded state. Hence, while OO is strongly stabilized by adsorption to 
the gas/water interface, this stabilization is not fully developed in the CC  OO transition 
state. 
By switching kop to kagg one can use equation 2.6 to estimate the kinetic barrier for 
aggregation of OO. This approach yields an activation barrier height of 46 kJ mol-1, 
corresponding to a transition state energy that is (16 + 46) kJ mol-1 = 62 kJ mol-1 above CC. 
Aggregation can be considered to be quasi-irreversible,61 implying that the free energy of 
aggregated Mb in our model is far below that of the metastable CC state (Figure 6C). 
 
2.3 Conclusions 
 
The experiments and kinetic simulations of this work provide insights into the 
conformational dynamics of a model protein (Mb) under conditions where interactions with 
gas/water interfaces are promoted by N2 sparging. Our results highlight the destabilizing 
effects of gas bubbles, as well as the propensity of the protein to aggregate under these 
conditions. Analysis of the HDX/MS data strongly suggests the involvement of globally 
unfolded conformers that are adsorbed to the surface of gas bubbles via interactions with 
previously buried nonpolar residues. This OO species represents a kinetic branching point 
from which the protein can either aggregate, or refold to the native state. 
The kinetic framework of Figure 6 describes the experimental data well (Figure 7), but 
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readers are reminded of the minimalist nature of our model. Many aspects are not 
considered in detail. For example, it seems possible that bubble-adsorbed OO is quite 
stable, and that the kinetic competition between refolding and aggregation only commences 
after this conformer is released into solution upon bubble bursting. Also, modeling 
aggregation as a first-order process with a fixed rate constant glosses over many of the 
complexities associated with this process. Similarly, describing EX2 dynamics via a single 
semi-unfolded state certainly represents an oversimplification.40,44 Despite these 
limitations, we feel that the model of Figure 6 provides a useful approximation of the 
protein dynamics in the presence of gas bubbles. 
HDX measurements clearly represent an interesting approach for exploring the properties 
of proteins at interfaces.62 This technology can provide insights that go beyond those 
obtainable from commonly used bulk spectroscopic methods.14,15,25-27,31 It is hoped that the 
approach introduced in this study will be useful for exploring protein dynamics and 
aggregation in industrial processes, where bubble-related degradation phenomena are 
commonly encountered.14,15,23-27  
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Chapter 3. Binding Interactions of Osteoprotegerin (OPG) with 
RANKL and Heparan Sulfate Studied by Hydrogen Exchange 
Mass Spectrometry 
 
3.1 Introduction 
 
Bone is one of the most vital connective tissues in vertebrates. It consists of a collagen 
matrix that is mineralized with hydroxyapatite ([Ca3(PO4)2]Ca(OH)2).
1 Bone takes on 
many roles; in conjunction with skeletal muscles it is essential for locomotion, it provides 
support for soft tissues, stores minerals, etc.2 Despite its rigid appearance, bone undergoes 
constant turnover which allows it to respond to mechanical and physiological stimuli.1 All 
these processes are part of a delicate balance between bone resorption mediated by 
osteoclasts, and bone formation mediated by osteoblasts.3 Bone remodeling is essential for 
growth, fracture healing, and for maintaining calcium homeostasis.4,5 An imbalance 
between bone resorption and formation gives rise to bone disease. Excessive osteoclast 
activity causes osteoporosis, while unchecked osteoblast activity results in osteopetrosis.6,7 
Osteoprotegerin (OPG), a soluble ~50 kDa glycoprotein secreted by osteoblasts, plays a 
central role during bone remodeling.8-11 Two other key proteins are RANK (receptor 
activator of nuclear factor-κB) and its binding partner RANKL (RANK ligand).12-14 OPG, 
RANKL, and RANK are part of a signaling network that regulates bone resorption by 
modulating osteoclast development and activation.14,15 RANK is a trimeric membrane 
protein on the surface of osteoclast precursors. Its ligand RANKL is a membrane protein 
expressed by osteoblasts. RANKL binding to RANK triggers the transformation of 
osteoclast precursors to active osteoclasts, which allows bone resorption to commence. 
OPG acts as a RANKL decoy receptor. By forming a high affinity RANKL/OPG complex, 
OPG suppresses RANKL/RANK interactions. In other words, OPG protects bone from 
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being resorbed by sequestering RANKL.14,15 An elevated RANKL:OPG ratio serves as a 
clinical marker for pathological osteoclastogenesis.16 
OPG can be dissected into several domains (Figure 1a).10,17 Four cysteine-rich domains 
(CRD1-CRD4) contain numerous intramolecular disulfide bonds. Asn178 in CRD4 
represents a glycosylation site.18 The second half of the sequence includes two death 
domains (DD1 and DD2). The C-terminal tail is basic due to a relatively high percentage 
of Arg and Lys residues. Cys400, the penultimate residue, allows the formation of a 
disulfide bond with Cys400’ of a second OPG chain.8,10,18,19 We will refer to this SS-linked 
homodimer as OPG2
SS. We distinguish this covalent dimer from OPGSH which is not 
covalently linked and instead possesses a free sulfhydryl group at Cys400. Both OPG2
SS 
and OPGSH bind RANKL with Kd values in the nM range.
19 OPG can also dimerize in the 
absence of the Cys400 linkage, forming noncovalent [OPGSH]2 complex.
19 The two death 
domains, as well as the tail domain, are thought to be involved in OPG dimerization.19 
X-ray crystallography has provided some insights into the interaction of OPG with 
RANKL.17,18 Unfortunately, this information only extends to truncated constructs because 
the full-length proteins have not been amenable to crystallographic investigations. Figures 
1b and 1c depict the structure of a 3:3 complex between the RANKL receptor-binding 
domain (grey) and the CRD1-CRD4 regions of OPG (colored). The central RANKL trimer 
consists of three -sandwiches that are linked by hydrophobic contacts. Each of the 
RANKL subunits interacts with one OPG chain. These interactions are mediated by 
segments 71TDSWHTSDECVYCSPVCKEL90 and 111RYLEIEFC118 in CRD2 and CRD3, 
respectively.17 Figure 1c shows the remaining OPG regions (DD1, DD2, Tail) in cartoon 
form due to the lack of crystallographic information for these segments.17 Given the 
propensity of OPG to dimerize,8,10,18,19 the main physiological binding scenario likely 
involves two subunits of the RANKL trimer that interact with one OPG dimer.18 The third 
RANKL subunit can bind a second OPG dimer, but likely with lower affinity since that 
interaction would only involve a single RANKL chain and a single OPG chain.19 
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Figure 1. (a) Mouse OPG sequence and domain architecture. Cys residues involved in 
disulfide bonds are shown in green. Basic residues in the DD2 and Tail domains are 
highlighted in blue, with those of particular importance for HS binding underlined.20 
Panels (b) and (c) show the X-ray structure of a complex consisting of three truncated OPG 
chains and trimeric truncated RANKL (pdb code 4E4D).
17 RANKL is depicted in gray, 
OPG is colored. Disulfides are highlighted in green. The crystallographic data available 
for OPG only cover the N-terminal cysteine-rich domains CRD1-CRD4. (b) View from the 
OPG N-terminal side. (c) Side view, with key contact regions highlighted in magenta for 
one of the OPG chains. Also shown in (c) are cartoons of the two OPG death domains 
(DD1 and DD2), and the tail domain with Cys400 that can form a disulfide with Cys400 
of another OPG chain. 
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OPG also interacts with heparan sulfate (HS),21,22 a linear glycosaminoglycan that is 
present on the surface of virtually all cell types. HS is involved in a wide range of regulatory 
functions.23-25 Of note, HS on the osteoblast surface participates in the regulation of bone 
remodeling.21 The presence of glucuronate and sulfate groups renders HS negatively 
charged. HS-protein contacts are generally mediated by electrostatic interactions with 
cationic (Lys/Arg-rich) regions,23,24,26 often resulting in conformational changes of the 
receptor protein.27 The basic tail domain of OPG has traditionally been considered to be 
the HS binding site, with affinities in the nM range.10,11,18,19,22,28 
Recent work (by our collaborator D.X.)20 demonstrated that HS binding to OPG involves 
not only the tail domain but also parts of DD2, consistent with the fact that DD2 also 
contains a high percentage of basic residues (Figure 1a). HS binding was demonstrated for 
both OPG2
SS and OPGSH. The interaction of HS with OPGSH resulted in dimerization, i.e., 
the formation of noncovalently bound [OPGSH]2. HS binding to OPG2
SS triggered structural 
changes, evident from a ~10% reduction in Rg measured by small angle X-ray scattering 
(SAXS). The SAXS profiles of HS-bound OPG2
SS and [OPGSH]2 were almost 
superimposable, suggesting similar structures. The presence of RANKL resulted in 
complexes containing HS, two OPG dimers, and one RANKL trimer. The data obtained 
were consistent with the view that HS at the osteoblast surface promotes OPG binding to 
RANKL via OPG sequestration and/or conformational changes.20 
As noted, thus far crystallographic information is only available for the CRD domains in 
the N-terminal region of OPG. Those data provide some insights into the RANKL binding 
sites on OPG.17,29 However, major knowledge gaps persist with respect to the OPG C-
terminal domains. For example, the exact location of HS binding sites in the C-terminal 
region, and the spatial relationship between CRD domains and death/tail domains remain 
largely unknown. Also, differences related to the dimerization of OPGSH and OPG2
SS, as 
well as details of the dimerization interface remain obscure.30 In addition, crystal structures 
may not always provide accurate structural information for solution phase protein-protein 
complexes due to crystal packing artifacts.31 Therefore, new experimental methods need to 
be introduced to resolve these conundrums. Hydrogen-deuterium exchange (HDX) mass 
spectrometry (MS) has emerged as a powerful tool to examine the structure and dynamics 
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of proteins in solution.32-37 HDX experiments monitor the exchange of backbone amide 
hydrogens with deuterium. Changes of exchange rates reflect the conformational alteration 
of protein influenced by ligand binding and/or protein-protein contacts.38-44 Although 
HDX-MS generally benefits from X-ray crystallographic information, the presence of high 
resolution structural data is not a prerequisite for the successful application of HDX-MS. 
In this work, we apply HDX-MS to explore and analyze the OPG system in the presence 
of HS and/or RANKL. The data reveal that HS and RANKL have different effects on 
OPGSH and OPG2
SS. Based on the observed dynamics changes of OPG under different 
condition, we were able to pinpoint the HS-binding site on OPG. We also propose a model 
that describes how HS regulates OPG dimerization and RANKL binding: formation of 
[OPGSH]2, induced by HS binding, reduces the entropy penalty of OPG-RANKL 
complexation. 
 
3.2  Experimental 
 
3.2.1 Materials  
 
Full-length mouse OPG was expressed in 293-freestyle cells (ThermoFisher Scientific). 
OPG2
SS and OPGSH were separated on a heparin-Sepharose column.20 Stable trimers of 
RANKL158-316 were expressed in E. coli. The proteins were purified as described,
20 yielding 
stock solutions of 8 mg mL-1 in 25 mM HEPES buffer with 150 mM NaCl at pH 7.1, and 
10 mg mL-1 in 20 mM Tris buffer and 150 mM NaCl at pH 7.5, respectively. HS was 
supplied as heparin-derived dodecasaccharide (Sigma, St. Louis, MO). Tris-(2-
carboxyethyl)-phosphineHCl (TCEP) and other reagents were from Sigma as well. 
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3.2.2 HDX Samples 
 
 HDX samples were prepared in 25 mM HEPES, 50 mM NaCl and 85 % D2O (HDX buffer) 
at pHread 7.1 at room temperature (22  1) C. All samples contained 8 M OPG2SS or 16 
M OPGSH. RANKL trimer was added at a concentration of  7.5 M, and HS at 11.4  M. 
One the basis of nM literature Kd values
11,19 for interactions with HS and RANKL,  OPG 
was ~99% saturated with its binding partners under HDX conditions. A stoichiometric 
excess of RANKL was chosen to suppress the presence of free OPG. This scenario 
precluded meaningful HDX measurements on RANKL because a significant fraction of 
RANKL chains remained unbound. The OPG response to ligand binding was probed by 
conducting HDX-MS on eight types of samples: (1) OPGSH without binding partners, (2) 
OPGSH + HS, OPGSH + HS + RANKL, (4) OPGSH + RANKL, (5) OPG2
SS without binding 
partners, (6) OPG2
SS + HS, (7) OPG2
SS + HS + RANKL, (8) OPG2
SS + RANKL. 10 L 
aliquots were removed from the HDX solutions at 10 s, 1 min, 10 min, 50 min, 100 min, 
200 min. In initial digestion experiments, we found that the high number of disulfides in 
the OPG CRD1-CRD4 region caused poor sequence coverage, a problem that is commonly 
encountered with SS-containing proteins.45-48 After extensive testing and optimization we 
settled on a disulfide reduction strategy involving TCEP.47,49 10 L aliquots were mixed in 
a 1:1 volume ratio with ice-cold quenching buffer (8 M urea and 1 M TCEPHCl) at a 
measured pH of 2.3. The samples were then flash frozen in liquid nitrogen and stored at     
-80 C. Prior to analysis the samples were thawed to 0 C, and the liquid samples were kept 
on ice for 5 min for TCEP-mediated disulfide reduction. The samples were then diluted 
with three volumes of aqueous formic acid (pH 2.3) to lower the TCEP concentration for 
protecting the downstream pepsin column. The resulting 60 L samples were analyzed as 
outlined below. The reduction/digestion workflow resulted in 60+ peptides for a sequence 
coverage of ~80%. The digestion patterns of OPG2
SS and OPGSH were slightly different. 
Although the use of TCEP significantly improved peptic digestion of the CRD regions, the 
number of peptides originating from these regions was significantly lower than in the 
DD1/DD2/Tail regions (Figures 2, 3). CRD regions contain 9 disulfide bonds which results 
in much lower peptide numbers compared to other regions.  Zero-time point samples (m0) 
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were produced by exposing pre-quenched OPG to D2O labeling solution. Maximally 
exchanged controls (m100) were generated by incubation of OPG in HDX solution for 24 h 
at pH 2.4 and 37 ˚C. In all other aspects, the m0 and m100 samples were treated like the 
regular time points. 
 
 
 
 
Figure 2. Peptic digestion map of OPGSH. Number of peptides = 62, coverage = 75%, 
redundancy = 3.4. The sequence numbering shown here includes the N-terminal signal 
peptide (residues 1-21). The protein used for the experiments of the current study started 
at residue 22. 
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Figure 3. Peptic digestion map of OPG2
SS. Number of peptides = 64, coverage = 86%, 
redundancy = 3.4. See comments regarding sequence numbering in the caption of Figure 
2. 
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3.2.3 HDX-MS Analysis 
 
60 L quenched aliquots were injected into a nanoACQUITY UPLC with HDX technology 
(Waters, Milford, MA) for digestion, desalting and peptide separation. Online digestions 
were performed on a POROS pepsin column (2.1 mm  30 mm, Applied Biosystems, 
Carlsbad, CA) at 15˚C. The resulting peptides were trapped on a guard column (BEH C18 
1.7 um, 2.1  5 mm) and separated on a reversed phase column (BEH C18 1.7 um, 1  100 
mm) using a water/acetonitrile gradient in the presence of 0.1% formic acid at 40 L       
min-1. Peptide mass spectra was recorded on a Waters Synapt G2 instrument with source 
and desolvation temperatures of 80 and 250 C, respectively. The cone voltage was set at 
20  V, and the electrospray voltage was 3 kV. The identity of each peptide was confirmed 
by MSE and PLGS 2.4.3 (Waters) in initial control experiments conducted without D2O. 
HDX kinetic profiles were analyzed by DynamX 3.0 (Waters) and plotted as centroid mass 
versus D2O exposure time. Deuteration levels are reported as HDX Percentage = (mt – 
m0)/(m100 – m0). All experiments were performed in triplicate. Error bars represent standard 
deviations. 
 
3.3  Results and Discussion 
 
3.3.1 HDX Isotope Distributions 
 
HDX-MS was employed to interrogate changes in the structure and dynamics of full-length 
OPGSH and OPG2
SS in response to HS and/or RANKL addition. As an example of 
unprocessed raw data, Figure 4 shows peptide 347-374, which covers parts of the DD2 and 
Tail regions. This peptide exhibited dramatically lowered HDX levels in the presence of 
HS and HS + RANKL for both OPGSH and OPG2
SS. The addition of RANKL alone did not 
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cause significant effects in this region. These data reaffirm that interactions with HS trigger 
major conformational changes in OPG,20 as suggested in previous studies.21,22 Similar to 
the behavior seen for all other peptides, Figure 4 reveals that OPG deuteration proceeds 
with unimodal H/D isotope distributions which reflect EX2 behavior. In other words, HDX 
is mediated by rapid H-bond opening/closing transition, with closing rate constants >> 1 s-
1,50 as commonly seen for many other proteins under native solvent conditions. 34-36 
The complete set of HDX kinetics recorded under all eight conditions is summarized in 
Figures 5 and 6. One striking feature in this data set are the relatively high exchange levels 
seen for the majority of the peptides. Typical globular proteins tend to possess rigid 
segments that remain incompletely deuterated even after hours of D2O incubation.
32-37 
OPG showed a very different behavior, as many peptides were ~50% labeled already after 
10 s. After 2 h, deuteration had gone to completion for all peptides, even in the presence 
of ligands. This behavior reflects the highly dynamic nature of OPG which has thus far 
precluded crystallization of the full-length protein.17,18 Difficulties of growing crystals 
from proteins that show high HDX levels have been noted previously.51  
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Figure 4. HDX mass spectra of OPGSH (top panels) and OPG2
SS (bottom panels), 
representing the eight experimental conditions tested in this work. These data are for 
peptide 347YALKHLKTSHFPKTVTHSLRKTMRFLHS374 (covering the DD2/Tail region) 
for an HDX labeling time of 10 s.   
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Figure 5. Deuteration kinetics of OPGSH under four different conditions (without ligands, 
with HS, with HS and RANKL, with RANKL), as noted in the legend. The figure is continued 
on the next page. 
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Figure 5. OPGSH deuteration kinetics – continuation from the previous page. 
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Figure 6. Deuteration kinetics of OPG2
SS under four different conditions (without ligands, 
with HS, with HS and RANKL, with RANKL), as noted in the legend. 
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Figure 6. OPG2
SS deuteration kinetics – continuation from the previous page. 
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3.3.2 Ligand-Induced Effects in the CRDs 
 
Representative examples taken from the complete HDX data set (Figure 5, 6) are 
highlighted in Figure 7, illustrating the behavior of various regions in OPGSH (left hand 
side) and OPG2
SS (right hand side). As noted above, the peptic cleavage patterns were 
somewhat different for the two forms. In Figure 7 an effort was made to compare OPGSH 
and OPG2
SS peptides that cover approximately the same regions. We will discuss these data 
by moving from the N- to the C-terminus, i.e., top to bottom of Figure 7. The data 
interpretation is guided by the tenet that ligand-protein or protein-protein interactions often 
(though not always) cause reduced HDX levels. These HDX changes tend to be most 
pronounced directly at the interaction site, but allosteric effects may take place as well.52-
55  
CRD1 (Figure 7, peptide 22-40) was found to be quite dynamic, with high deuteration 
levels that were insensitive to addition of HS and/or RANKL. This behavior is consistent 
with the view that CRD1 is not involved in HS or RANKL binding, both in the case of 
OPGHS and OPG2
SS.17,18,20-22  
CRD2 in OPGHS appeared to be largely unstructured, regardless of the presence of HS or 
RANKL (Figure 7, 86-98) In OPG2
SS this segment was much more protected even without 
ligands (Figure 7, peptide 86-103). This behavior strongly suggests the occurrence of 
noncovalent CRD2-CRD2’ binding interactions in OPG2SS, promoted by the “pre-
alignment” of the two OPG chains by the C-terminal disulfide. It is well established that 
SS-bonds can allosterically trigger distant protein-protein contacts by reducing the entropic 
penalty that would otherwise be associated with these protein-protein contacts.56 
Significant additional stabilization of CRD2 in OPG2
SS was observed after addition of 
RANKL; this effect was independent of HS. Hence, OPG2
SS binds RANKL in an HS-
independent fashion, confirming earlier size exclusion chromatography data.20 Very 
similar effects were seen for CRD3 (Figure 7, 130-142). These findings are consistent with 
the crystallographic data that identified CRD2 and CRD3 as RANKL binding region.17,18 
Importantly, the structural data of Figure 1 imply that binding of the two OPG chains in 
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OPG2
SS to RANKL is incompatible with the presence of CRD2-CRD2’ contacts.17,18 Our 
data thus imply that these contacts in OPG2
SS have to dissociate for RANKL binding to 
take place.  
Figure 7. HDX difference plots for a labeling time of t = 10 s. Panels (a) - (c): HDX 
changes for OPGSH relative to ligand-free OPGSH. Negative values indicate less 
deuteration after addition of binding partners, i.e., HS and/or RANKL. (d) Comparison of 
ligand-free OPGSH and ligand-free OPG2SS. Panels (e) – (g): HDX changes for OPG2SS 
relative to ligand-free OPG2SS. 
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For OPGSH our data do not indicate a strong involvement of CRD2 in RANKL binding, 
despite minor binding-related effects in CRD2 peptide 52-97 (Figure 7). Hence, CRD3 
seems to be the dominant RANKL binding element in OPGSH. Sadly, CRD3 is not covered 
in the peptide map of OPGSH, such that these contacts cannot be verified directly. 
Nonetheless, from the deuteration behavior of CRD2 (discussed above), it is clear that the 
OPG-RANKL binding interactions must be somewhat different for OPGSH and OPG2
SS. In 
the former case, RANKL contacts are formed mainly with CRD2. For OPG2
SS both CRD2 
and CRD3 mediate binding, as seen in the crystal structures.17,18 
For CRD4 in OPGSH, deuteration was significantly suppressed by HS, while RANKL did 
not have any effects. Even stronger protection was seen for CRD4 in OPG2
SS, regardless 
of the solution conditions (Figure 7, 157-178 and 153-182). We attribute this behavior to 
HS-induced dimerization of OPGSH.20 The data of Figure 7 strongly suggest that these 
[OPGSH]2 species interact through CRD4-CRD4’ contacts. The relatively strong protection 
seen in this region for OPG2
SS (regardless of ligands) suggests that similar CRD4-CRD4’ 
contacts are also triggered by the presence of the Cys400 disulfide bond. The lack of such 
CRD4-CRD4’ contacts in the available X-ray structures likely reflects the absence of C-
terminal linkages in the truncated crystal constructs.17,18 Formation of such CRD4-
CRD4’contacts represents an allosteric effect, as it is caused by distant factors, i.e., HS 
binding the case of OPGSH, and the presence of a C-terminal SS bond in the case of OPG2
SS. 
As noted above, these C-terminal contacts “pre-align” the two OPG chains and thereby 
lower the entropic penalty associated with the formation of noncovalent intra-chain 
bonds.56 
 
3.3.3 Ligand Effects in the Non-Crystallized Regions 
 
DD1 and DD2 were relatively disordered in both OPGSH and OPG2
SS, regardless of the 
solution conditions (Figure 7, 207-222). Close inspection of the HDX profiles in these 
regions nonetheless reveals interesting features. OPG2
SS showed slightly more protection 
after addition of HS and/or RANKL. Considering the small magnitude of these changes, 
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they likely do not represent direct ligand-protein interactions, but weak allosteric 
stabilization from distant binding events57-60 (i.e., RANKL binding to CRD2 and CRD3, 
as well as HS binding closer to the C-terminus). DD1 in OPGSH did not respond to isolated 
RANKL, while HS caused a marked reduction in deuteration for early labeling times 
(Figure 7, 207-222). Additional stabilization was observed upon RANKL addition to the 
HS-containing sample. This stabilization likely originates from HS-induced RANKL 
binding to CRD3 (see above). 
HS significantly suppressed deuteration in the range of residues 350-384 for OPGSH and 
OPG2
SS, consistent with electrostatically-mediated HS binding in this region (Figure 7, 
347-371).20 Farther towards the C-terminus, the Cys400-Cys400’ linkage caused a marked 
stabilization for OPG2
SS, with additional stabilization after HS binding (Figure 7, 378-384). 
In ligand-free OPGSH this segment was much more dynamic, with slight stabilization by 
HS and a surprisingly large additional stabilization under HS + RANKL conditions. 
  
3.3.4 HDX Difference Plots.  
 
A complementary perspective of the effects associated with OPG ligand binding and 
dimerization can be obtained by studying HDX differences for all the available peptides. 
We will focus on data for t = 10 s (Figure 8), where many of the distinguishing features 
were more pronounced than at later time points (Figure 5, 6). The most prominent feature 
in the difference plots are the negative values in the DD2 and Tail regions of both OPGSH 
and OPG2
SS (Figure 8, a, b, e, f), arising from HS binding to these regions.20 RANKL 
binding to OPGSH caused slightly reduced deuteration in CRD2 (Figure 8b, c). More 
pronounced effects were evident for CRD3 in OPG2
SS (  8f, g). A direct comparison 
between ligand-free OPGSH and OPG2
SS reveals an intricate pattern, consistent with slight 
stabilization of the Tail and DD1 regions after formation of the Cys400 disulfide bond 
(Figure 8d). Two possible reasons can cause this effect: First, the Tail domain could be part 
of the dimerization interface since it is reasonable to deduce the dimerization interface 
includes the adjacent region of cys400. However, DD1 domain is unlikely also to be a part 
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of the dimerization interface. The stoichiometry between OPG2
SS and RANKL trimer is 
more favorable at 1:1 ratio19, suggesting each monomer in the OPG2
SS would bind to 
separated binding sites on the same RANKL trimer. The distance between two monomers 
is over 50 Å. It is implausible that two DD1 domains on different monomers remain in 
contact while their neighbor domains are separated by such a large distance. That makes 
the stabilization on DD1 must due to an allosteric effect induced by dimerization.  
The sparse appearance of this data set arises from differences in the OPGSH and OPG2
SS 
digestion patterns, keeping in mind that deuteration differences can only be calculated for 
peptides that are exactly matched therefore not all peptic HDX data is presented in Figure 
8.  
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Figure 8. HDX difference plots for a labeling time of t = 10 s. Panels (a) - (c): HDX 
changes for OPGSH relative to ligand-free OPGSH. Negative values indicate less 
deuteration after addition of binding partners, i.e., HS and/or RANKL. (d) Comparison of 
ligand-free OPGSH and ligand-free OPG2
SS. Panels (e) – (g): HDX changes for OPG2SS 
relative to ligand-free OPG2
SS. 
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3.4 Conclusions 
 
Figure 9 provides a structural interpretation of our HDX-MS data in cartoon form. With no 
ligand (HS and/or RANKL) present, OPGSH remains monomeric and highly dynamic, 
especially in the CRD domains that contain the RANKL binding region. (Figure 9a) Under 
these conditions, formation of a OPG-RANKL complex would be associated with a large 
entropic penalty. This might be the reason why OPGSH has a lower affinity compared to 
OPG2
SS. In contrast, HS-induced [OPGSH]2 formation proceeds with HS-mediated contacts 
in the tail domain. Under these conditions the two OPGSH chains are pre-aligned for ligand 
binding. This pre-alignment is triggered by HS binding in the tail domain, but it is 
synergistically supported by the establishment of CRD4-CRD4’ contacts (Figure 7, peptide 
157-178), likely via hydrophobic interactions. The formation of [OPGSH]2 complex reduces 
the entropy penalty of subsequent RANKL binding. In this way, HS can regulate the 
binding affinity of OPGSH (or [OPGSH]2) for RANKL. Interestingly, once RANKL is bound 
to the HS-containing [OPGSH]2, it appears to stabilize the HS binding region even further 
(Figure 7). Hence, the presence of HS favors RANKL binding, while conversely the 
presence of RANKL favors HS binding. This mutual stabilization of two distinct binding 
partners will become even more evident in the following Chapter that deals with calcium-
mediated peptide interactions in a S100 protein. 
Figure 9b illustrates the proposed binding pattern for OPG2
SS to RANKL/HS. In contrast 
to OPGSH, OPG2
SS has already been “aligned” by dimerization. Therefore, the binding of 
HS does not strengthen the RANKL binding affinity of OPG2
SS. However, similar to 
OPGSH, HS also rigidify OPG2
SS N-terminal domains which includes Tail domain, DD1 
domain. DD2 domain is also affected but to a lesser extent (Figure 7 and 8). The region 
with suppressed deuteration correspond to the HS binding region, in agreement previous 
site-directed mutagenesis experiments.30 Another interesting feature evident from our data 
is that non-covalent CRD2-CRD2’ interactions in OPG2SS have to dissociate first in order 
to allow OPG2
SS interactions with RANKL. In the absence of these dissociation events the 
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RANKL binding site would be blocked, as evident from the X-ray structural data of Figure 
1. 
In conclusion, this study reports new structural insights into the RANKL/OPG/HS 
regulatory system. It can be expected that these new revelations can lead to the discovery 
of the more detailed regulatory mechanism of OPG in the human body and offer the 
opportunity to develop therapeutic approaches for tackling osteoporosis and related 
disorders. 
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Figure 9. Summary of proposed changes in structure and dynamics of OPG in response to 
HS and RANKL binding. (a) HS binding to OPGSH triggers formation of a [OPGSH]2 
complex, this complex subsequently binds RANKL. (b) HS binding to OPG2
SS promotes 
stabilization and inter-chain contacts; subsequent RANKL binding requires some of these 
contacts (CRD2-CRD2’) to dissociate. Each panel shows two OPG chains, domains are 
represented as boxes. Note how some of these boxes are in direct contact with one another 
(indicating noncovalent inter-domain contacts), while others are separated by a wide gap 
(representing weaker or no contacts). 
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Chapter 4. Calcium-Mediated Control of S100 Proteins: 
Allosteric Communication via an Agitator/Signal Blocking 
Mechanism 
 
4.1  Introduction 
 
Signaling proteins possess specific sites for binding their biological targets, such as nucleic 
acids or other proteins. Many of these interactions are controlled by allosteric effectors,1-3 
i.e., species that modulate the protein’s target affinity by interacting with locations remote 
from the target binding site.4-6 The dysregulation of allosteric interactions can lead to 
cancer and other diseases.7 Also, allostery is a central element of drug action 
mechanisms.8,9  
Classical models of allostery envision that effector binding triggers conformational 
changes that cause distant target binding sites to open or close.1,2,4 Recent studies have 
expanded this view by emphasizing the role of conformational dynamics.10-12 For example, 
it has been proposed that proteins fluctuate between co-existing conformers, and that 
allosteric effectors shift these equilibria towards structures with higher or lower target 
affinities.6,13-16 Regardless of the exact mechanism, allostery requires the transmission of 
signals to target binding sites, often over tens of Ångstroms.11,15 Such signals travel along 
dynamically coupled residues.16,18,19 Allosteric signal propagation pathways have been 
identified on the basis of mutational17 and evolutionary data,18 NMR spectroscopy,16,19-22 
X-ray crystallography,1,23,24 molecular dynamics (MD) simulations,6,9,25-30 and hydrogen-
deuterium exchange (HDX) mass spectrometry (MS).31-34 Even after allosteric pathways 
have been identified, however, the exact mechanisms by which remote sites communicate 
often remains unclear. 
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Calcium represents one of the most common allosteric regulators. The intracellular Ca2+ 
concentration under resting conditions is low, but it rises sharply following stimuli that 
cause the opening of membrane channels. This Ca2+ influx can activate signaling proteins, 
allowing them to bind their targets. Subsequent deactivation relies on membrane pumps 
that return the calcium concentration to its resting value, such that protein-target complexes 
dissociate again.35 
A particularly important group of calcium-dependent signaling proteins is the S100 family 
which is involved in numerous functions and diseases.36-38 Here we focus on S100A11, a 
typical homo-dimeric S100 family member that binds four Ca2+ and two target proteins.39 
One of these targets40,41 is annexin A2, a protein that interacts with the plasma membrane.42 
Calcium-loaded S100A11 can link two annexin A2 chains, thereby forming a complex 
required for membrane repair, specifically in cancer cells.43,44 
Each S100A11 subunit comprises four helices. The helix III/IV loop forms a high-affinity 
EF-hand calcium binding site. A lower affinity pseudo EF-hand is formed by the helix I/II 
loop (Figure 1a).35,45 In the Ca2+-bound form helices III/IV adopt a near-perpendicular 
orientation that results in an open target binding site. Figure 1b shows the structure of 
S100A11 with four Ca2+ and two annexin peptides.39 We will refer to this complex as [Ca4 
S100 Ax2]. Square brackets indicate components that are bound in a complex, the annexin 
peptide is denoted as Ax, and “A11” is omitted to streamline the notation. In apo-S100, 
helices III/IV are in a more antiparallel orientation, resulting in a closed target binding site 
that precludes interactions with Ax (Figure 1c).46 Similar transitions take place for many 
other Ca2+-dependent proteins.35,47 
The cooperative nature of allosteric regulation can be illustrated by using a thermodynamic 
cycle.48-50 Figure 1d considers two possible pathways for the conversion of apo-S100 to 
[Ca4 S100 Ax2]. Steps 1 and 2 represents the “canonical” scenario where metalation takes 
place first, followed by Ax binding. In this case calcium enhances the protein’s Ax binding 
affinity by G = -RT ln CCa, where the factor CCa > 1 reflects how the Ax binding 
equilibrium responds to the presence of calcium.48,49 Alternatively, one may consider a 
pathway where Ax binds first (step 3), followed by metalation (step 4). In this second 
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scenario, Ax enhances the metal binding affinity by G = -RT ln CAx.48,49,51 Thus, Ca2+ 
binding enhances the target affinity, and target binding enhances the Ca2+ affinity. This 
implies that allosteric signals must be able to travel from effector sites to target binding 
sites and vice versa. Both scenarios are associated with the same affinity enhancement, 
because CCa = CAx = C.
48-50 For the system considered here C  10.46,51-53  
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Figure 1. (a) Sequence of rabbit S100A11; helices and calcium binding sites are indicated; 
side chains involved in Ca2+ binding are underlined. (b) Crystal structure 1QLS39 of 
S100A11 bound to four Ca2+ and two annexin peptides (Ax). (c) NMR structure of apo-
S100A11 (pdb file 1NSH).46 (d) Thermodynamic cycle, illustrating the transition between 
apo-S100 and [Ca4 S100 Ax2] along two paths. Steps 1 & 2 refer to Ca
2+ binding followed 
by Ax binding. Steps 3 & 4 refer to Ax binding followed by Ca2+ binding. The overall 
equilibrium constant for complex formation is the same along both paths, implying that 
KCa (CCa KAx) = KAx (CAx KCa) such that CCa = CAx = C. 
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A number of studies have explored Ca2+-dependent allosteric effects in S100 family 
members and other EF-hand proteins35,54-57 The mechanism by which metal binding sites 
control target binding sites over a substantial distance  nonetheless remains poorly 
understood.46,58 For the system considered here, this distance is roughly 26 Å (measured 
from the center of an Ax helix to the EF-hand Ca2+ in the same subunit)39 Simply speaking, 
the field is dominated by the view that calcium loss enhances the conformational freedom 
of the EF- and pseudo EF-hands, and that this increased flexibility triggers a sequence of 
events that culminates in target binding site closure. 
Here we scrutinized the mechanism of S100 allosteric regulation by employing 
microsecond molecular dynamics (MD) simulations in explicit water, complemented by 
hydrogen/deuterium exchange mass spectrometry (HDX/MS). Protein structure and 
dynamics were probed in the presence/absence of calcium and Ax, corresponding to the 
complexes [Ca4 S100 Ax2], [Ca4 S100], [S100 Ax2] and apo-S100. Our data reveal an 
unexpected regulatory mechanism. Closure of the target binding site represents the 
culmination of an allosteric cascade that does not originate at the metalation sites. Instead, 
binding site closure is triggered by structural perturbations emanating from a labile salt 
bridge that acts as incessantly active “agitator”. Bound calcium stabilizes the target binding 
sites in an open conformation by blocking allosteric signals produced by the agitator. To 
our knowledge, the current work marks the first time that such an allosteric mechanism has 
been documented.  
 
4.2  Methods 
 
4.2.1 Proteins and Reagents 
 
Rabbit S100A11 was expressed and purified as described.46,59,60 As in previous work,61 a 
C9S variant was used to avoid inappropriate disulfide formation. The expected monomer 
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mass (11281 Da) was verified by MS (11281.5  1) Da. Ax (acetyl-STVHEILSKLSLEGD) 
was synthesized by BioBasic (Markham, ON). This peptide was used because of its higher 
solubility and binding affinity,61 compared to the annexin A1 peptide in the 1QLS X-ray 
structure.39 D2O (Aldrich, St. Louis, MO), KCl (Caledon, Georgetown, ON), HEPES, 
EDTA (Sigma), CaCl2, and HCl (Caledon) were used as received. 
 
4.2.2 HDX Mass Spectrometry 
 
Deuteration was performed at 23  1 C in 90 % D2O, 50 mM KCl, 20 mM HEPES, at a 
pH meter reading of 7.1. These solution conditions were chosen to ensure consistency with 
previous NMR studies, which demonstrated that background electrolyte concentrations >> 
50 mM can interfere with Ca2+ binding.46,61 The protein concentration was 2.5 μM (as 
dimer). Other components were added as needed, i.e., 5 mM CaCl2 for experiments 
conducted in the presence of Ca2+, 0.2 mM EDTA for Ca2+-free samples, and with or 
without 70 M Ax. All concentrations refer to the final values under HDX conditions. 
From published dissociation constants it can be estimated that ~99.5 % of the metalation 
sites were occupied in the Ca2+ containing solutions,62 and ~95 % of the protein was bound 
to Ax in [Ca4 S100 Ax2] samples.
61 100 μL aliquots were removed at various time points 
between 1 min and 2 h after initiation of labeling. The aliquots were quenched to pH 2.3 
by addition of HCl on ice, flash frozen in liquid nitrogen, and stored at - 80 ˚ C. The aliquots 
were thawed to ~ 0˚C and injected into an HDX nanoACQUITY UPLC63 (Waters, Milford, 
MA). Digestion was performed on a 2.1 mm  30 mm POROS pepsin column (Applied 
Biosystems, Carlsbad, CA) at 15˚C. Peptides were trapped on a Waters BEH C18 (1.7 m, 
2.1  5 mm) column, and separated on a BEH C18 (1.7 m, 1  100 mm) column using a 
water/acetonitrile gradient with 0.1% formic acid at 40 L min-1. Data analysis focused on 
17 peptides that cover the sequence in a contiguous fashion (Figure 2). Peptide masses 
were measured on a Waters Synapt G2 Q-TOF mass spectrometer. Peptide identities were 
confirmed by MS/MS. For correction of in-exchange, zero time point controls (m0) were 
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performed by exposing the protein to labeling buffer under quench conditions. Fully 
exchanged controls (m100) were prepared by incubation in labeling buffer at pH 2.4 and 
37 ˚C for 24 h. HDX temporal profiles were obtained from centroid mass values at time t, 
mt, obtained by DynamX 3.0 (Waters). Deuteration levels are reported as percent 
deuteration = (mt -m0)/(m100 -m0), where mt represented the centroid mass of a peptide at 
time t. All samples displayed uncorrelated HDX with gradual shifts of the isotope 
envelopes to higher mass, as commonly seen in the EX2 regime.64 All HDX data represent 
an average of triplicate measurements. Error bars indicate standard deviations. 
 
 
Figure 2. Peptic digestion map of S100A11, illustrating the peptides that were used for 
HDX/MS data analysis. 
 
4.2.3 MD Simulations 
 
MD simulations were conducted using GROMACS 5 with GPU acceleration65 at 298 K. 
The coordinates of human S100A11 bound to four Ca2+ and two annexin peptides (pdb file 
1QLS)39 served as starting structure for all runs. Human S1000A11 and the rabbit variant 
used in our HDX/MS experiments have slightly different sequences (84% sequence 
identity). To ensure that MD results and HDX/MS data were directly comparable we 
swapped several amino acids in the 1QLS starting structure using the mutagenesis and 
sculpting routines implemented in PyMol (Schrödinger), as detailed in Figure 3. Similarly, 
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the annexin A1 peptide of the 1QLS structure was transformed to the homologous Ax 
sequence. Simulations were conducted using the CHARMM 36 force field66 with TIP3P 
water.67 This combination has previously been shown to yield reliable folding and 
equilibrium dynamics.68 The protein was placed in a periodic box with a minimum distance 
of 7 Å between protein and the box surface. ~8000 water molecules were added, as well as 
70 mM K+ and Cl-, plus additional ions to ensure charge neutrality. After one round of 
energy minimization atomic velocities were initiated from a Maxwell-Boltzmann 
distribution with random seeds. This was followed by 100 ps NVT and NPT equilibration 
runs. Production runs were conducted with a 2 fs time step, using a Parrinello-Rahman 
barostat and Berendsen thermostat.69 Bonds were constrained by the linear constraint 
solver algorithm.70 Short-range electrostatic and van der Waals cutoffs were set to 10 Å. 
Long-range electrostatics were treated using Particle Mesh Ewald summation,71 with PME 
order = 4 and Fourier spacing = 0.16 nm. Two independent 1 s simulations were 
conducted for each of the conditions [Ca4 S100 Ax2], [Ca4 S100], [S100 Ax2] and apo-
S100, for a total of eight 1 s runs.  Major structural changes were observed only for apo-
S100, prompting us to perform an additional 200 ns run for this species to verify 
reproducibility. All repeat runs employed slightly different starting coordinates and initial 
velocities. 
 
 
         1          11         21         31         41 
Figure 3. Sequence comparison of porcine (1QLS)39 and rabbit (1NSH)46 S100A11. Amino 
acids that differ are highlighted in red. Also shown is the sequence used for the MD 
simulations of this work. It corresponds to the rabbit variant, except for the C-terminus 
where the shorter STQK element of the porcine protein was retained. This shorter C-
terminus permitted the use of a smaller simulation box with less water, thereby significantly 
reducing computational cost. This figure also defines the residue numbering used in this 
study.46 
 
         1          11         21         31         41 
pig   MA KRPTETERCI ESLIAIFQKH AGRDGNNTKI SKTEFLIFMN TELAAFTQNQ  
rabbit   SRPTETERCI ESLIAVFQKY AGKDGHSVTL SKTEFLSFMN TELAAFTKNQ  
MD       SRPTETERCI ESLIAVFQKY AGKDGHSVTL SKTEFLSFMN TELAAFTKNQ  
 
         51         61         71         81         91 
pig      KDPGVLDRMM KKLDLDSDGQ LDFQEFLNLI GGLAIACHDS FIKSTQK 
rabbit   KDPGVLDRMM KKLDLNSDGQ LDFQEFLNLI GGLAVACHES FVKAAPPQKR F 
MD       KDPGVLDRMM KKLDLNSDGQ LDFQEFLNLI GGLAVACHES FVKSTQK 
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4.3  Results and Discussion 
 
4.3.1 Molecular Dynamics Simulations 
 
We conducted 1 s MD simulations on [Ca4 S100 Ax2], [Ca4 S100], [S100 Ax2], and apo-
S100. Using the [Ca4 S100 Ax2] X-ray coordinates
39 as starting point, structural changes 
were triggered by removal of calcium and/or Ax. All simulations converged towards 
relaxed (meta)stable conformers within ~0.5 s (Figure 4). As a benchmark, we verified 
that [Ca4 S100 Ax2] maintained a conformation close to the initial X-ray structure (Figure 
5a). Runs without calcium and Ax produced structures consistent with the apo-S100 NMR 
coordinates (Figure 5b). These tests confirm that the MD conditions used are adequate. 
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Figure 4: RMSD plots, illustrating how the protein structures evolved during 1 s 
simulations, relative to the common starting conformation. Panels (a), (b) display data for 
two sets of replicate MD runs. Occasional large fluctuations (e.g., in (a) for Ca4 S100 
around 350 ns) arise from fraying of terminal helices. In (c), data from the 500 ns - 1 s 
range from both sets of simulations were averaged. All RMSDs were calculated for 
backbone heavy atoms from both subunits, focusing on helical regions. The sequence range 
used was I: 6-22, II: 34-48, III: 56-63, IV: 74-86. 
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Target binding site conformations can be characterized by examining the orientation of 
helices III/IV (Figure 5c). For helix angles of ~115 or less the binding sites are open and 
capable of accommodating Ax. Larger values (around 155) represent closed binding 
sites.39,46,72 Most S100 structural studies39,46,72 reported the same angle for both subunits in 
the homodimer due to symmetry constraints imposed during analysis73 (Figure 5c, gray 
bars). However, in solution74 and in our unconstrained MD simulations the helix III/IV and 
helix III’/IV’ angles will not be identical. Figure 5c therefore displays two angles for each 
MD structure. Runs for [Ca4 S100 Ax2] and [Ca4 S100] maintained open binding sites with 
angles close to those of the corresponding experimental structures.39,72 Experimental data 
for [S100 Ax2] are not available; the two MD runs conducted for this species culminated 
in somewhat different outcomes. In the first instance both binding sites stayed open. The 
second [S100 Ax2] run yielded dissimilar angles of ~85 for helices III/IV (open), and 
~144 for III’/IV’ (closed). Finally, the simulated apo-S100 angles all corresponded to 
closed binding sites (Figure 5b), as noted above.46  
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Figure 5. (a) 1 s MD structure of [Ca4 S100A11 Ax2] (magenta) and X-ray structure 
(gray, 1QLS).39 (b) 1 s MD apo-S100 structure (red) and NMR structure (gray, 1NSH 
#5).46 (c) Helix III/IV and III’/IV’ angles. Experimental values are from pdb files 1QLS,39 
2LUC,72 and 1NSH.73 MD data were averaged over the final 0.5 s windows of 1 s 
simulation runs, and data are shown separately for subunits A and B from two independent 
runs for each condition. Error bars represent standard deviations. 
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4.3.2 Details of MD Structures 
 
Figure 6 provides a closer look at examples of t = 1 s MD structures, using a layout 
consistent with that of Figure 1d. [Ca4 S100 Ax2] exhibited a globular fold with a well-
developed hydrophobic core (Figure 6a). Both Ax peptides remained tightly associated 
with the hydrophobic target binding pockets. The EF-hand calcium binding loops at the 
protein surface were firmly rooted in the core via nonpolar anchor residues (L63 and L71). 
Each EF-hand was in close contact with an intricately packed “shoulder” consisting of 
D57/K32/M60/L71. In this shoulder D57 and K32 were connected by a salt bridge, while 
K32, M60, and L71 were linked by close hydrophobic contacts. The K32-D57 salt bridge 
as well as the adjacent packing contacts are highly conserved in S100 proteins.74 It may 
seem counter-intuitive to have lysine (a “hydrophilic” residue) involved in hydrophobic 
packing, but motifs of this type are common, as governed by the aliphatic nature of the 
CαH-CH2-CH2-CH2-CH2- moiety in lysine.
75  
[S100 Ax2] showed partial disruption of the D57/K32/M60/L71 shoulder (Figure 6b). For 
the structure exemplified in Figure 6, only one of the target binding sites retained tight Ax 
contacts. The second site adopted a closed structure, while the corresponding Ax peptide 
remained loosely associated via residual nonpolar contacts (colored in Figure 6b). Closure 
of this binding sites was a gradual process that extended over ~0.5 s (Figure 7A (q)). The 
perturbed target interactions suggest that the corresponding Ax peptide is poised to separate 
from the complex, although dissociation did not take place on the time scale of our 
simulations. Still, the [S100 Ax2] MD structure clearly represents an intermediate en route 
towards target-free apo-S100. 
Except for the absence of Ax, the [Ca4 S100] 1 s structure was very similar to that of [Ca4 
S100 Ax2]. Both possess open target binding sites and intact D57/K32/M60/L71 shoulders 
(Figure 6c). This is different from apo-S100, where target binding site closure in both 
subunits was associated with complete disintegration of the D57/K32/M60/L71 shoulders 
(Figure 6d). 
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Figure 6. 1 s MD structures for the four simulation conditions. Structures and 
equilibrium arrows are arranged in accordance with Figure 1d. One subunit in each panel 
is grayed out to reduce clutter. Hydrophobic side chains (I, V, L, F, M, A) are displayed as 
sticks. Spacefill representation was used for residues constituting the D57/K32/M60/L71 
“shoulder”, which is intact only in panels (a, c). Ca2+ and Ax are displayed in magenta. 
Dashed lines indicate the helix III/IV orientation, which defines whether target binding 
sites are open (a, c), or closed (b, d). 
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Figure 7(A). Complete 1 s trajectory data, displaying inter-atomic distances for the four 
MD conditions, as noted along the top. Each panel displays data for chain A (dark red) and 
chain B (dark green) within the S100 dimer. 
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Figure 7(B). Complete 1 s trajectory data, as on the preceding page, but for an 
independent set of MD simulations. The significance of the arrows in (w), (x) at ~450 ns is 
discussed in the caption of Figure 10. 
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4.3.3 Allosteric Control of Target Binding Sites 
 
Our MD data capture a central aspect of calcium-mediated allosteric control, i.e., the fact 
that in apo-S100 the target binding sites collapse to a closed conformation that cannot bind 
Ax (Figure 6d). This is in contrast to [Ca4 S100] where calcium maintains open target 
binding sites that are primed for Ax interactions (Figure 6c). 
For deciphering the mechanism of allostery it is essential to identify the driving force for 
binding site closure. This event is not associated with the formation of stable salt bridges. 
Also, changes in H-bonding are minor (Table 1).54,55 However, [Ca4 S100] possesses 
numerous solvent exposed nonpolar residues in the target binding sites (Figure 8a). Binding 
site closure dramatically reduces the accessibility of these residues and allows them to form 
hydrophobic contacts (A45, F46, V55, M59, L63, A86, F91, Figure 8b). Hence, the main 
driving force for binding site closure is the hydrophobic effect (Figure 8a, b).76-79 At the 
risk of sounding naïve, we point out parallels between this [Ca4 S100]  apo-S100 closure 
(Figure 8a, b) and another “allosteric” process, i.e., a spring-loaded mouse trap that snaps 
close after a rodent pulls at the bait. Bait movements do not provide the driving force for 
the closure event. Instead, pulling at the bait triggers the release of energy stored in the 
spring. Analogously, Ca2+ loss does not provide the driving force for binding site closure. 
Instead, Ca2+ loss triggers the release of free energy associated with hydrophobic collapse 
of the binding site (Figure 8b).77-79 Within this picture, the exposed nonpolar sites in [Ca4 
S100] serve a purpose analogous to that of the spring in the trap. This digression prompts 
two questions: (i) How does the presence of Ca2+ prevent binding site closure? (ii) How 
does the absence of Ca2+ trigger binding site closure? Both can be addressed by examining 
the temporal behavior of selected atom distances (Figure 8c), with primary focus on [Ca4 
S100] and apo-S100 (Figure 8d-u). 
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Table 1 (continued on subsequent pages): H-bonds derived from the final 0.5 s of MD 
simulation runs. The first column lists the NH donor, the following columns list the main 
chain (m) and side chain (s) oxygen acceptors. Acceptor notation is as follows: 
10Im(A97,B89) refers to residue 10, isoleucine, main chain, 97% H-bonded in chain A, 
89% H-bonded in chain B. Data are shown only for NH sites that are H-bonded more than 
20% in total; contributions below 2% were omitted. For the sake of simplicity, this table 
only refers to one set of MD replicates, corresponding to the runs highlighted in Figure 6. 
NH [Ca4 S100 Ax2] [Ca4 S100] [S100 Ax2] apo-S100 
2R    11Es(A0, B65)         
4T    2Rm(A30, B0)   2Rm(A7, B24) 
7Es(A18, B0)  
7Es(A21, B0)   
5E 42Es(A100, B23) 
2Rm(A0, B4)  
42Es(A100, B22)   42Es(A40, B100) 
5Es(A4, B0)  
5Es(A88, B28)   
6T 42Es(A100, B66)   42Es(A100, B96)   42Es(A78, B100)      
7E 4Ts(A0, B9) 
7Es(A0, B31)  
4Ts(A0, B26)   4Ts(A79, B81)   4Tm(A34, B21)   
8R 4Tm(A0, B80)   4Tm(A42, B77) 
5Em(A3, B0)  
4Tm(A32, B57)   4Tm(A23, B20) 
5Em(A3, B4)  
9C 5Em(A90, B86) 
6Tm(A0, B2)  
5Em(A75, B82) 
6Tm(A4, B4)  
5Em(A88, B89)   5Em(A93, B81) 
6Tm(A0, B2)  
10I 6Tm(A98, B76) 
7Em(A0, B2)  
6Tm(A78, B84)   6Tm(A98, B84)   6Tm(A98, B89)   
11E 7Em(A99, B86)   7Em(A99, B99)   7Em(A96, B100)   7Em(A97, B96)   
12S 8Rm(A95, B94)   8Rm(A93, B93)   8Rm(A96, B89)   8Rm(A95, B94)   
13L 9Cm(A97, B95)   9Cm(A91, B92)   9Cm(A96, B72) 
10Im(A0, B3)  
9Cm(A98, B94)   
14I 10Im(A94, B77)   10Im(A97, B89)   10Im(A93, B92)   10Im(A97, B95)   
15A 11Em(A97, B98)   11Em(A94, B96)   11Em(A99, B95)   11Em(A97, B97)   
16V 12Sm(A94, B97)   12Sm(A95, B93)   12Sm(A85, B82)   12Sm(A99, B97)   
17F 13Lm(A65, B62) 
14Im(A3, B0)  
13Lm(A97, B79)   13Lm(A58, B74)   13Lm(A95, B88)   
18Q 14Im(A96, B97)   14Im(A94, B95)   14Im(A100, B97)   14Im(A100, B99)   
19K 15Am(A30, B40) 
16Vm(A25, B26)  
15Am(A58, B58) 
16Vm(A16, B13)  
15Am(A63, B79) 
16Vm(A6, B8)  
15Am(A87, B76) 
16Vm(A2, B4)  
20Y 17Fm(A47, B49) 
16Vm(A0, B6)  
16Vm(A42, B22) 
17Fm(A4, B14)  
16Vm(A15, B79) 
17Fm(A32, B0)  
16Vm(A65, B56) 
17Fm(A4, B13)  
21A 18Qm(A76, B31) 
17Fm(A0, B41)  
17Fm(A25, B24) 
18Qm(A35, B49)  
17Fm(A74, B81) 
18Qm(A6, B3)  
17Fm(A91, B55) 
18Qm(A0, B14)  
22G 18Q(A0, B23) 
34Es(A0, B32)  
34Es(A90, B89)   18Qm(A2, B72) 
29Tm(A77, B0) 
19Km(A0, B5)  
18Qm(A75, B18) 
19Km(A3, B0) 
29Tm(A0, B45)  
23K          19Km(A35, B0) 
21Am(A2, B0) 
27Sm(A21, B0) 
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24D 21Am(A54, B17) 
24Ds(A3, B10)  
24Ds(A29, B28)   27Sm(A29, B0)      
25G          22Gm(A0, B14) 
24Ds(A0, B22)  
26H          23Km(A0, B13) 
18Qm(A0, B14)  
27S    18Qs(A0, B21) 
24Dm(A0, B5)  
24Dm(A20, B0)   21Am(A2, B12) 
23Km(A17, B3) 
22Gm(A0, B8) 
24D(A0, B3) 
28V             
29T 24Ds(A99, B0 )      22Gm(A43, B0)   27Ss(A42, B37) 
21Am(A22, B0)  
30L 71Lm(A99, B92)   71Lm(A94, B86)   71Lm(A96, B20)   71Lm(A64, B73)   
31S 34Es(A100, B76)   34Es(A99, B98)   20Ys(A0, B11) 
34Es(A0, B22)  
   
32K       69Gm(A28, B89) 
70Qs(A41, B0 )  
69Gm(A75, B81) 
70Qs(A3, B0)  
33T       31Ss(A0%, B4%) 
68Ds(A0%, B2%) 
68Dm(A0%, B14) 
   
34E    31Ss(A33, B22) 
31Sm(A0, B2)  
31Ss(A20, B31) 
31Sm(A3, B5)  
31Ss(A23, B0) 
31Sm(A5, B0)  
35F 31Sm(A99, B95)   31Sm(A99, B99)   31Sm(A98, B68) 
32Km(A0, B12)  
31Sm(A94, B93)   
36L 32Km(A96, B94)   32Km(A97, B93)   32Km(A97, B75)   32Km(A95, B99)   
37S 33Tm(A83, B76)   33Tm(A87, B74)   33Tm(A95, B81)   33Tm(A87, B92)   
38F 34Em(A95, B85)   34Em(A88, B82)   34Em(A96, B96)   34Em(A89, B96)   
39M 35Fm(A99, B94)   35Fm(A99, B99)   35Fm(A99, B100)   35Fm(A99, B98)   
40N 36Lm(A79, B79) 
37Sm(A7, B7)  
36Lm(A98, B95)   36Lm(A99, B96)   36Lm(A90, B83) 
37Sm(A0, B4)  
41T 37Sm(A16, B18) 
38Fm(A65, B52)  
37Sm(A46, B30) 
38Fm(A32, B41)  
37Sm(A73, B68) 
38Fm(A8, B11)  
37Sm(A14, B15) 
38Fm(A61, B57)  
42E 38Fm(A31, B21) 
41Ts(A5, B10)  
38Fm(A70, B54) 
41Ts(A0, B4)  
38Fm(A99, B99)   38Fm(A28, B7) 
41Ts(A9, B18)  
43L 38Fm(A57, B63) 
39Mm(A6, B4)  
38Fm(A17, B32) 
39Mm(A23, B17)  
39Mm(A98, B96)   38Fm(A53, B76) 
39Mm(A9, B0)  
44A 41Tm(A35, B41) 
42Em(A0, B3)  
41Tm(A31, B0)   41Tm(A4, B0) 
42Em(A26, B0)  
41Tm(A26, B63) 
39Mm(A6, B0)  
45A    39Mm(A24, B0) 
40Nm(A13, B0)  
   41Tm(A28, B0)   
46F    39Mm(A26, B0) 
43Lm(A2, B0)  
   42Em(A32, B0) 
43Lm(A5, B0)  
47T 43Lm(A93, B75) 
44Am(A0, B8)  
43Lm(A42, B92)   43Lm(A96, B34)   43Lm(A79, B85) 
44Am(A2, B0)  
48K 44Am(A88, B5) 
45Am(A2, B47)  
44Am(A36, B5) 
45Am(A25, B45)  
44Am(A89, B33) 
45Am(A0, B22)  
44Am(A49, B62) 
45Am(A15, B7)  
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49N 45Am(A39, B0) 
46Fm(A32, B0)  
44Am(A0, B93) 
45Am(A41, B0) 
46Fm(A31, B0)  
45Am(A76, B45) 
46Fm(A10, B4) 
11Ss(A0, B29) 
45Am(A37, B56) 
46Fm(A28, B21)  
50Q 46Fm(A31, B0) 
47Tm(A45, B0)  
46Fm(A32, B0) 
47Tm(A36, B12) 
47Ts(A0, B17)  
46Fm(A79, B20) 
47Tm(A6, B29)  
46Fm(A10, B18) 
47Tm(A51, B34) 
51K          90Ss(A36, B62)   
52D          50Qs(A8, B0) 
90Ss(A39, B0)  
54G 52Ds(A48, B0)      57Ds(A0, B87)   52Ds(A60, B53)   
55V 52Dm(A0, B27) 
53Pm(A0, B3)  
         
56L    52Dm(A0, B97)         
57D    53Pm(A0, B82)         
58R 54Gm(A90, B48)   54Gm(A87, B86)   54Gm(A85, B71) 
55Vm(A0, B6)  
54Gm(A88, B91)   
59M 55Vm(A97, B96)   55Vm(A97, B99)   55Vm(A91, B30) 
56Lm(A0, B31)  
55Vm(A72, B49) 
56Lm(A3, B7)  
60M 56Lm(A91, B89)   56Lm(A95, B98)   56Lm(A96, B46) 
57Dm(A0, B23)  
56Lm(A93, B93)   
61K 57Dm(A83, B79) 
58Rm(A0, B4)  
57Dm(A84, B96)   57Dm(A94, B0)   57Dm(A84, B94) 
58Rm(A2, B0)  
62K 58Rm(A86, B82) 
59Mm(A3, B4)  
58Rm(A89, B85) 
59Mm(A0, B3)  
58Rm(A91, B0) 
59Mm(A2, B0)  
58Rm(A85, B80) 
59Mm(A3, B3)  
63L 59Mm(A88, B74) 
60Mm(A3, B10)  
59Mm(A92, B73) 
60Mm(A2, B12)  
59Mm(A87, B0) 
60Mm(A3, B0)  
59Mm(A90, B74) 
60Mm(A0, B4)  
64D 60Mm(A46, B34) 
61Km(A12, B13)  
60Mm(A53, B70) 
61Km(A7, B5)  
60Mm(A46, B0) 
61Km(A17, B0)  
60Mm(A80, B69) 
61Km(A3, B8)  
65L 75Es(A69, B56)   75Es(A63, B75)   60Mm(A57, B0) 
64Ds(A27, B0)  
61Km(A79, B60) 
62Km(A7, B20)  
66N 64Ds(A13, B29) 
75Es(A82, B59)  
64Ds(A13, B14) 
75Es(A82, B85)  
64Ds(A0, B37)   62Km(A72, B54) 
63Lm(A13, B12)  
67S 64Ds(A20, B22) 
64Dm(A6, B6)  
64Ds(A20, B30) 
64Dm(A7, B0)  
64Ds(A0, B2) 
64Dm(A0, B33)  
63Lm(A11, B0) 
64Dm(A3, B0) 
75Es(A7, B0) 
68D 64Ds(A25, B30) 
66Ns(A3, B5) 
68Ds(A3, B3) 
64Ds(A27, B37) 
66Ns(A4, B6)  
      
69G 64Ds(A98, B85)   64Ds(A99, B99)   67Ss(A31, B18) 
68Ds(A14, B6)  
67Ss(A56, B0)   
70Q 64Ds(A3, B5) 
68Ds(A84, B85)  
68Ds(A91, B0) 
64Ds(A0, B88)   
      
71L 30Lm(A100, B94)   30Lm(A100, B96)   30Lm(A93, B93)   30Lm(A96, B98)   
72D 75Es(A100, B99)   75Es(A100, B100)   75Es(A89, B59)   75Es(A63, B75) 
73F 28Vm(A0, B43)   28Vm(A0, B26)         
74Q             
75E             
76F 72Dm(A96, B98)   72Dm(A98, B97)   72Dm(A98, B97)   72Dm(A97, B98)   
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77L 73Fm(A93, B99)   73Fm(A91, B96)   73Fm(A99, B97)   73Fm(A99, B99)   
78N 74Qm(A15, B95) 
75Em(A50, B0)  
74Qm(A19, B86) 
75Em(A36, B0)  
74Qm(A93, B83)   74Qm(A90, B89)   
79L 75Em(A5, B89) 
76Fm(A52, B0)  
75Em(A2, B87) 
76Fm(A52, B0)  
75Em(A91, B84) 
76Fm(A0, B3)  
75Em(A83, B83) 
76Fm(A2, B2)  
80I 76Fm(A34, B100)   76Fm(A40, B99)   76Fm(A100, B98)   76Fm(A99, B99)   
81G 77Lm(A99, B96)   77Lm(A96, B87)   77Lm(A96, B94)   77Lm(A93, B88)   
82G 78Nm(A89, B83) 
79Lm(A0, B2)  
78Nm(A73, B59) 
79Lm(A4, B11)  
78Nm(A77, B84) 
79Lm(A4, B0)  
78Nm(A73, B63) 
79Lm(A5, B9)  
83L 79Lm(A98, B95)   79Lm(A98, B90)   79Lm(A92, B90)   79Lm(A84, B65) 
80Im(A0, B4)  
84A 80Im(A97, B96)   80Im(A95, B91)   80Im(A92, B97)   80Im(A96, B94)   
85V 81Gm(A91, B94)   81Gm(A83, B59) 
82Gm(A0, B6)  
81Gm(A93, B98)   81Gm(A98, B97)   
86A 82Gm(A91, B91)   82Gm(A80, B39) 
83Lm(A0, B3)  
82Gm(A73, B94)   82Gm(A83, B89)   
87C 83Lm(A98, B98)   83Lm(A97, B96)   83Lm(A88, B99) 
84Am(A5, B0)  
83Lm(A96, B96)   
88H 84Am(A94, B94)   84Am(A81, B96) 
85Vm(A9, B0)  
84Am(A75, B95) 
85Vm(A9, B0)  
84Am(A94, B95)   
89E 85Vm(A95, B91)   85Vm(A80, B95)   85Vm(A67, B97)   85Vm(A97, B97)   
90S 86Am(A87, B76) 
87Cm(A2, B0)  
86Am(A71, B90) 
87Cm(A2, B0)  
86Am(A53, B83) 
87Cm(A3, B0)  
86Am(A93, B89)   
91F 87Cm(A97, B93) 
88Hm(A0, B2)  
87Cm(A84, B88) 
88Hm(A3, B0)  
87Cm(A82, B93) 
88Hm(A4, B3)  
87Cm(A95, B88) 
88Hm(A0, B4)  
92V 88Hm(A62, B96)   88Hm(A84, B92)   88Hm(A67, B97) 
89Em(A5, B0)  
88Hm(A97, B87)   
93K 89Em(A18, B86) 
88Hm(A64, B0)  
89Em(A75, B70) 
90Sm(A9, B9)  
89Em(A59, B81) 
90Sm(A15, B0) 
88Hm(A0, B2)  
89Em(A95, B76) 
88Hm(A0, B2)  
94S 90Sm(A3, B41) 
91Fm(A18, B14) 
89Em(A5, B0) 
90Sm(A17, B6) 
91Fm(A32, B48)  
90Sm(A30, B53) 
91Fm(A34, B19)  
90Sm(A72, B45) 
91Fm(A11, B18)  
95T 89Em(A62, B2) 
90Sm(A16, B7) 
91Fm(A0, B21) 
92Vm(A0, B17) 
90Sm(A56, B80) 
91Fm(A2, B0)  
91Fm(A11, B28) 
92Vm(A11, B24) 
90Sm(A26, B0) 
91Fm(A48, B20) 
92Vm(A20, B24)  
96Q 92Vm(A0, B19) 
93Km(A0, B3) 
94Ss(A0, B3) 
      92Vm(A16, B14) 
93Km(A19, B3) 
94Ss(A0, B7) 
97K     
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Figure 8. (a) 1 s MD structure of [Ca4 S100]. Exposed nonpolar residues in the target 
binding site are highlighted in red. (b) 1 s MD structure of apo-S100. (c) Atoms used for 
tracking protein conformational dynamics. (d-i) Atom distances for [Ca4 S100]. Panels (j-
o) and (p-u) display two apo-S100 runs. Dashed lines indicate target binding site closing 
midpoint (panels n, t). 
127 
 
Our simulations reveal that the metalation sites became more dynamic after calcium loss, 
exemplified by the D68-F73 distance fluctuations in Figure 8d/j/p. F73 represents a quasi-
stationary reference point, while D68 is in the center of the EF-hand. Importantly, the 
enhanced D68 dynamics are not directly correlated with target binding site closure events 
(Figure 8n, t). This lack of correlation reflects the fact that much of the EF-hand is only 
weakly coupled to the protein core (Figure 9a). The same is true for the pseudo EF-hand 
loops, which extend far into the solvent (Figure 8a, b). Thus, the problem has to be 
investigated from a broader perspective, by also examining events taking place elsewhere 
in the protein. 
The egregious exposure of hydrophobic residues in the [Ca4 S100] target binding sites can 
be maintained because of favorable nonpolar packing between helices II and III adjacent 
to the EF-hands. This hydrophobic cluster includes L63, it is capped off by the 
D57/K32/M60/L71 shoulder, and it suspends helix III in the open conformation (Figure 
9a). Surprisingly, in [Ca4 S100] the shoulder can undergo large perturbations without 
triggering irreversible binding site closure, exemplified by events between t = 50 and 80 
ns (Figure 8e-i). During this time the K32-D57 salt bridge underwent dissociation, M60 
moved away from L71, L63/L71 drifted apart, and the binding site began to close (evident 
from a decreasing V55-A86 distance, Figure 8h). A snapshot taken at t = 70 ns illustrates 
the severity of these perturbations, which even included disruption of D64 and N66 metal 
ligation in the EF-hand (Figure 9b). Remarkably, these events stalled at t  70 ns. Instead 
of closing all the way, the binding site returned to the fully open state, and the 
D57/K32/M60/L71 shoulder underwent re-assembly (Figure 8e-h). The observed behavior 
suggests that a key event is not permitted to happen in [Ca4 S100], which would otherwise 
allow binding site closure to go to completion. 
Our data suggest that binding site closure in [Ca4 S100] is prevented by a lack of L63-F73 
distance fluctuations (more support for this assertion is provided in the next paragraph). As 
noted, L63 represents an EF-hand anchor. F73 remains virtually stationary under all 
conditions. In [Ca4 S100] L63 and F73 are locked at a distance around 11 Å (Figure 8i). 
The invariability of this distance results from constraints imposed by calcium-protein 
contacts in the EF-hand (Figure 9a). In summary, in [Ca4 S100] hydrophobic packing of 
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the shoulder/EF-hand region suspends helix III in the open state. This arrangement is 
stabilized by L63-F73 distance constraints that arise from Ca2+-induced rigidification of 
adjacent to residues (Figures 1a, 9a). Thus, calcium ensures that perturbations in the 
shoulder get “blocked” as they propagate from K32 towards the core (note the gradually 
diminishing amplitude at t  70 ns when going from Figure 8e to 4i). In this way calcium 
prevents irreversible binding site closure in [Ca4 S100]. Another example of such a blocked 
propagation process, observed in an independent [Ca4 S100] run, is highlighted in Figure 
10. 
 
Figure 9. Close-up views of the EF-hand calcium binding region during MD runs. (a) [Ca4 
S100] at 1 s. (b) [Ca4 S100] while undergoing a structural perturbation at t  70 ns. (c) 
apo-S100. Side chains comprising the D57/K32/M60/L71 shoulder, as well as those of L63 
and F73 are shown as spheres. EF-hand side chains involved in calcium binding are shown 
as sticks, and labeled in red. 
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Figure 10. MD simulation data generated in a [Ca4 S100] run. This figure illustrates the 
blocked propagation of a structural perturbation, resembling the events illustrated in 
Figure 4d-j of the main text (the data shown here are from an independent replicate). The 
K32-D57 salt bridge temporarily dissociates at t  350 ns (panel b). This is followed by 
the transient disruption of M60-L71 contacts, with a subsequent fluctuation in L63-L71 
packing (indicated by asterisks in panels c, d). Further propagation of the perturbation is 
blocked, as the L63-F73 distance remains almost constant because of Ca2+-induced 
rigidification. As a result, the target binding site stays open instead of undergoing 
hydrophobically-driven closure.  
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In apo-S100 all closing transitions were irreversible. Although different MD runs showed 
slightly different sequences, each closing event was associated with major L63-F73 
distance fluctuations and a subsequent L63-F73 distance increase from ~11 Å to ~14 Å. 
We will highlight two runs in more detail. In the first example disassembly of the shoulder 
took place gradually over ~40 ns (Figure 8k-m). During this time the K32-D57 salt bridge 
dissociated and M60 moved away from L71. The L63-L71 distance underwent a major 
fluctuation which extended to L63-F73. The latter event triggered closure of the target 
binding site at t  25 ns (dashed line, Figure 8n). In another apo-S100 run (Figure 8q-u) 
dissociation of the K32-D57 salt bridge took place within the first few nanoseconds, 
followed by repositioning of M60. Alterations in L63-L71 distance were minor, but a 
change in L63-F73 distance within the initial 10 ns allowed the target binding site to move 
into a semi-closed state. At t  60 ns the binding site closed completely, while 
simultaneously the L63-F73 distance increased to ~14 Å. Our data suggest that L63-F73 
distance fluctuations are the key prerequisite for target binding site closure, rather than the 
L63-F73 distance increase from 11 Å to 14 Å. This is evident from the fact that at the 
transition midpoints of Figure 8 o,u the L63-F73 distances are still relatively small, around 
12 Å. Also, after the binding sites had closed, the L63-F73 distance could temporarily 
return from 14 Å back to 12 Å (Figure 7B, panel x, chain A, 300-600 ns). Numerous other 
distances were scrutinized, but no events were correlated with binding site closure as 
clearly as the L63/F73 behavior. 
We conclude that target binding site closure in apo-S100 is the result of a domino cascade 
that starts with disintegration of the D57/K32/M60/L71 shoulder. The labile K32-D57 salt 
bridge represents the primary “agitator”. Dissociation of this salt bridge is followed by 
M60 swinging away from L71. In the absence of Ca2+ the hydrophobic packing of residues 
next to L63 and F73 is not stabilized by EF-hand mediated rigidification, allowing the 
formation of extensive new hydrophobic contacts as the target binding sites close (Figure 
8b). Complete 1 s trajectories for all four conditions are provided in Figure 7. Those data 
confirm a high propensity of the K32-D57 salt bridge to undergo reversible dissociation 
even for [Ca4 S100 Ax2], in line with the labile nature of this contact in [Ca4 S100]. 
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The apo-S100 closing cascades highlighted in Figure 8 refer to collapse of the first binding 
site in the dimer. In both instances the collapse of the second site took place ca. 70 ns after 
the first one. Those subsequent closure events also required L63-F73 distance fluctuations 
(Supporting Figure S7). In a third apo-S100 run both sites underwent initial closure roughly 
simultaneously around 25 ns, but chain A settled into a fully relaxed closed state only after 
~450 ns (Figures 7, 11). Taken together, these observations suggest that closure events 
affecting the two binding sites within a S100 dimer are not directly coupled to one another. 
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Figure 11: Initial 170 ns time segments of three different apo-S100 MD runs, displaying 
inter-atomic distances for the two S100 subunits, chain A (dark red) and chain B (dark 
green). Arrows in (d, i, n) indicate target binding site closure events. Arrows in (e, j, o) 
highlight L63-F73 distance fluctuations/alterations that precede these closing events or 
occur quasi-simultaneously with them. The chain A target binding site in (n) fully settles 
into its irreversibly closed state only after ~450 ns; consistent with all other apo-S100 runs, 
this closure event is associated with a major L63-F73 fluctuation (see arrows in Supporting 
Figure 7, panels w, x)  
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4.3.4 Probing Calcium and Target Binding by HDX/MS 
 
Our MD simulations successfully captured ns - s events associated with allosteric control. 
However, conformational fluctuations in solution can extend to time scales that are orders 
of magnitude longer,80 stretching into realms that are inaccessible by MD techniques.68,81 
A comprehensive characterization of protein dynamics thus requires the application of 
complementary approaches that report on dynamics taking place on a wider time range. 
Continuous labeling HDX/MS is well suited for this purpose. This technique monitors the 
deuteration of backbone amides. HDX/MS reports on protein dynamics because NH 
deuteration is mediated by H-bond fluctuations that are coupled to backbone motions. EX2 
rate constants can be expressed as kHDX = (kop/kcl) kch, where kop and kcl are H-bond 
opening/closing rate constants, while kch reflects deuteration of unprotected sites.
82 
Deuteration kinetics thus provide a cumulative picture of H-bond fluctuations that occur 
on time scales of sub-microseconds to seconds and beyond.80 To be clear, the use of 
HDX/MS in our experiments does not imply that changes in H-bonding constitute the 
mechanistic foundation of S100 allostery. Rather, as noted throughout the text, 
rearrangements of hydrophobic moieties were identified as the primary factor for signal 
propagation and binding site closure (Figure 8). HDX/MS nonetheless provides a window 
into allosteric events, because different allosteric switching states exhibit different HDX 
fingerprints. 
HDX/MS conditions were designed to mimic those of the MD investigations. Comparison 
of the deuteration kinetics for [Ca4 S100 Ax2], [Ca4 S100], [S100 Ax2] and apo-S100 
reveals that the addition of calcium and/or Ax solicits highly complex responses throughout 
the protein (Figures 12, 13). These range from stabilizing effects to local destabilization. 
Similarly convoluted HDX patterns have been reported for other allosteric proteins.83-86 
The HDX/MS data are also consistent with NMR-based HDX experiments on the apo and 
Ca4 forms of S100B.
87 
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Figure 12. Deuteration kinetics of S100A11 segments (complete data set). Each panel 
contains data for all four experimental conditions. Data points represent the average of 
three independent measurements. Standard deviations are shown as error bars.  
Biexponential fits (solid lines) were included for illustrative purposes only. 
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Figure 13. Graphic representation of the experimental deuteration percentages for t = 10 
min. The structures shown represent 1 s MD conformations. Top row (a-d): absolute 
deuteration percentages. Bottom row (e-g): deuteration difference relative to apo-S100. 
For these difference maps, red represents increased deuteration compared to the apo-
protein, blue represents reduced deuteration. 
 
The most pertinent HDX/MS results are summarized in Figure 14. Some regions were 
highly protected under all conditions, exemplified by peptide 14-17 which is part of the 
tightly packed core (Figure 14a). Other segments, such as the N- and C-termini were 
completely deuterated already at the earliest time point, attesting to their flexible nature 
without stable H-bonds (Figure 14d). Calcium and Ax reduced the deuteration of the 
pseudo EF-hand in an additive fashion, demonstrating that both binding partners stabilize 
the H-bonding network in this area (Figure 14b). The EF-hand showed pronounced synergy 
between calcium and Ax-mediated stabilization. This region exhibited complete 
deuteration in apo-S100, some protection in [Ca4 S100], and dramatically reduced HDX in 
[Ca4 S100 Ax2] (Figure 14c). Unlike for the pseudo EF-hand, Ax alone did not cause 
significant changes in the EF-hand (Figure 14b and 14c). 
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Figure 14. HDX/MS kinetics of selected segments. (a) Residues 14-17 in helix I, (b) 
residues 18-30 in the pseudo EF-hand, (c) residues 66-71 in the EF-hand calcium binding 
site, (d) residues 92-101, representing the C-terminus. Each panel contains results for four 
experimental conditions. Data points represent the average of three independent 
measurements. Standard deviations are shown as error bars. Bi-exponential fits (solid 
lines) were included for illustrative purposes. 
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The discussion of our MD data in the preceding sections implicitly focused on allosteric 
control along steps 1 and 2 of the thermodynamic cycle of Figure 1d, where Ca2+ facilitates 
Ax binding by preventing closure of the target binding site. The calcium-mediated Ax 
affinity enhancement is G = -RT ln C. The HDX protection patterns of Figure 14b and 
14c reflect the flipside of allosteric control, i.e., the fact that Ax governs the calcium 
affinity in accordance with steps 3 and 4 of Figure 1d.48-50 Deuteration level changes in 
[Ca4 S100 Ax2] relative to [Ca4 S100] are consistent with Ax-mediated calcium binding 
enhancement, as Ax allosterically stabilizes the H-bonding network in all four calcium-
binding sites. This is evident from the observation that HDX levels of the metalation sites 
are lower when Ax and Ca2+ are present together, than when only Ca2+ is bound (Figure 
14b, 14c). Our MD data reveal the basis of this allosteric reciprocity.50 The presence of Ax 
in [S100 Ax2] ensures that several residues close to the calcium binding region maintain a 
“holo-like” orientation, e.g., the D57/K32/M60/L71 shoulder does not get disrupted to the 
same extent as in apo-S100 (Figure 6b and 6d). Ax enhances the calcium binding affinity 
by G = -RT ln C. Earlier work suggests that C  10,46,51-53 such that the allosteric 
stabilization associated with either pathway (1/2 or 3/4 in Figure 1d) is roughly 6 kJ mol-1.  
 
4.3.5 HDX Experiments and MD-Derived H-Bond Patterns 
 
Classical models of backbone NH deuteration envision that the transient disruption of 
amide H-bonds is the sole determinant of HDX rates.88 Recent studies suggest that other 
factors such as solvent accessibility and electrostatics may also exert some influence, but 
the central role of H-bond fluctuations remains undisputed.80,81,89,90 It is interesting to 
compare experimental deuteration values with MD-derived H-bonding patterns. Figure 15 
shows HDX percentages measured after 10 minutes of labeling. Also shown are MD data 
reflecting the fraction of time that each backbone amide is H-bonded. This H-bonding 
analysis takes into account all possible protein acceptor sites, including carboxylates which 
participate in NH contacts in the calcium binding loops (Figure 7). Readers are reminded 
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that the MD data only reflect a 1 s time window, while the experimental data report on 
fluctuations that extend to seconds and beyond.80 HDX/MS can therefore pinpoint regions 
undergoing slow conformational dynamics that go undetected in MD simulations. 
 
Figure 15. Comparison of HDX/MS data at t = 10 min (round symbols, plotted vs. peptide 
midpoint) and MD H-bonding patterns for (a) [Ca4 S100 Ax2], (b) [Ca4 S100], (c) [S100 
Ax2], and (d) apo-S100. Solid lines represent the time fraction during which backbone NH 
sites are H-bonded during the final 0.5 s of the MD simulations (data are shown for both 
subunits and for two independent MD runs). The H-bonding scale is inverted, such that 
high HDX levels are aligned with low H-bond percentages. 
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Simulated H-bond percentages and experimental HDX levels in Figure 15 are remarkably 
consistent throughout much of the sequence range. All four conditions resulted in weak H-
bonding (high HDX levels) at the termini and inter-helical loops. H-bonds in helical 
regions tended to be more stable (with lower HDX levels). In the EF-hand around residue 
70 simulated H-bonds were well developed (with low HDX values) for [Ca4 S100 Ax2] 
and [Ca4 S100]. Less pronounced H-bonding (and elevated HDX levels) were encountered 
in this region for [S100 Ax2] and apo-S100. Thus, both experiments and MD simulations 
revealed that calcium significantly stabilizes H-bonds in the vicinity of the EF-hands. 
Diverging behavior between simulated H-bond patterns and experimental HDX data were 
observed in a few instances. The double-headed arrows in Figure 15 highlight segments 
where simulations indicate well-developed H-bonds, while the experimental HDX data 
show a lack of protection. This behavior was observed around residue 88 close to the center 
of helix IV for all conditions, with the exception of apo-S100 (Figure 15d). Similar effects 
were also encountered for [Ca4 S100] and apo-S100 in the vicinity of residue 62 (Figure 
15b, 15d). Thus, regions marked with double-headed arrows undergo H-bond 
opening/closing transitions that take place on time scales much slower than the s regime 
explored in our simulations. Overall, Figure 15 nonetheless demonstrates a high level of 
consistency between simulated and measured H-bond properties. 
 
4.4  Conclusions 
 
Allosteric proteins possess communication pathways that allow the transfer of signals 
between remote sites along dynamically coupled residues.1,6,9,11,15-21,23-34,91 Previous studies 
implicitly assumed that the starting point of any given communication pathway coincides 
with an effector binding site. Hence, it is commonly thought that effector binding (or loss) 
constitutes the initial trigger event that subsequently propagates via a domino-like cascade, 
culminating in conformational changes elsewhere in the protein. Figure 16a schematically 
illustrates this classical paradigm, assuming a scenario where the bound effector promotes 
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an open target binding site. Loss of the effector (magenta) triggers a cascade of events 
along an allosteric pathway (blue), ultimately causing closure of the target binding site 
(red). 
Figure 16a represents a reasonable description of allosteric regulation for many proteins, 
as suggested by similar cartoons in numerous reviews and biochemistry texts.8,92,93 
However, calcium-mediated S100 control follows a different mechanism, as uncovered in 
this work. Closure of the target binding site is the result of an allosteric cascade that is not 
triggered by the effector. Instead, the K32-D57 salt bridge acts as an “agitator” that is labile 
and destabilizes packing interactions of adjacent residues. Random thermal fluctuations of 
this agitator represent the initial trigger of the allosteric cascade. The agitator is coupled to 
the target binding site by dynamically linked residues that allow the initial perturbation to 
propagate, resulting in closure of the binding site (Figure 16b). The effector (calcium) acts 
by blocking signals emanating from the agitator, i.e., by interfering with the transmission 
of allosteric signals (Figure 16c). This blockage is achieved by damping the fluctuations of 
residues involved in the allosteric cascade. 
Figure 16d summarizes details of the signal blocking mechanism uncovered in this study. 
In [Ca4 S100] helix III is suspended in the open conformation by packing interactions 
within the D57/K32/M60/L71 shoulder. These interactions extend to adjacent hydrophobic 
sites such as L63 and L71, and to helix II which is positioned behind helix III (Figure 16d, 
left hand side). The top center panel of Figure 16d illustrates events taking place upon 
calcium loss from [Ca4 S100]. The K32/D57 salt bridge is labile and undergoes 
dissociation/re-association transitions which represent the initial trigger event (marked as 
“1” in the allosteric cascade of Figure 16d). This agitation propagates via disruption of 
K32/M60 (“2”) and M60/L71 (“3”) interactions. The breakdown of packing interactions 
becomes irreversible once L63/F73 undergo a major distance fluctuation (“4”), allowing 
helix III to swing downward such that the target binding site closes (“5”). This closing 
event is driven by the burial of hydrophobic sites between helices III and IV. If calcium is 
present (Figure 16d, bottom center) structural disturbances generated at the K32-D57 
agitator cannot proceed beyond L71, because metal-protein contacts in the EF-hand 
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rigidify the L63-F73 distance. Hence, the allosteric cascade comes to a halt, and the target 
binding site remains open. 
There is prior evidence for scenarios where allosteric pathways are affected by interactions 
with other communication channels. For example, the outcome of effector binding can be 
altered by affinity modulators, efficacy modulators, agonists, or antagonists.8,92,93 The 
current work further expands the spectrum of possible branched signaling scenarios. We 
uncover a mechanism where a constitutively active agitator communicates with a remote 
target binding site. Only in the absence of calcium does the resulting signal cascade cause 
binding site closure, while bound calcium dampens the motion of key residues along the 
allosteric pathway. Thus, the effector (calcium) works by blocking the information flow 
between agitator and target binding site. 
In general terms, we propose that an allosteric agitator can be defined as follows: (i) An 
agitator is a structurally labile element that undergoes incessant opening/closing 
fluctuations. (ii) The open state of the agitator destabilizes adjacent noncovalent contacts. 
(iii) Coupling of the agitator to dynamically linked residues allows the propagation of 
conformational perturbations in a domino-like fashion, ultimately affecting the 
structure/dynamics of a remote protein region (e.g., a target binding site). (iv) Allosteric 
effectors can block signals emanating from the agitator by stabilization (rigidification) of 
elements along the propagation pathway. 
In future work, it will be interesting to determine if similar agitator/blocking scenarios also 
apply to other classes of allosteric proteins. The combined MD and HDX/MS strategy 
applied here should be well suited for endeavors of this type. 
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Figure 16. (a) Conventional allosteric mechanism, where effector loss triggers closing of 
a remote target binding site. Numbers 1, 2, ... refer to structural events associated with the 
signaling cascade. Panels (b) and (c): Generic representation of the mechanism uncovered 
in this study. (b) A fluctuating agitator triggers an allosteric cascade that causes binding 
site closure. (c) The presence of an effector blocks the cascade, such that the binding site 
stays open. (d) Cartoon summary of the calcium-mediated blocking mechanism in 
S100A11. The upper pathway results in binding site closure. In the lower pathway calcium 
in the EF-hand blocks signal transfer, information flow stalls, and the binding site stays 
open. 
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Chapter 5. Conclusions 
 
5.1  Summary 
 
The work in this thesis mainly describes how measurements of protein dynamics can be 
used to extract information related to the general behavior of proteins in different 
biophysical/biochemical contexts. In general, experimental methods to study protein 
dynamics are still relatively limited. Many traditional protein analysis methods can either 
only examine protein under particular conditions (X-ray crystallography, Cryo-EM) or 
provide limited information (UV/CD spectrometry). This situation makes HDX-MS a very 
attractive experimental method for probing protein dynamics, even with limited 
background information. HDX/MS relies on the principle that unfolded and/or highly 
dynamic regions undergo faster deuteration than tightly folded segments. The broad 
usability and ease of operation get HDX-MS more and more attention in various aspects, 
evident from the steadily growing number of laboratories who have adopted this technique. 
Here we present three different protein systems that have been investigated by HDX-MS. 
These studies cover three different perspectives: protein folding, protein-ligand 
interactions and allosteric effects. Also, MD simulations are used as a parallel tool in the 
last project. MD simulations are capable of providing detailed information at the atomic 
level which well complements the peptidic resolution in bottom-up HDX-MS.    
In Chapter 2, a common phenomenon that creates trouble in the pharmaceutical industry 
was explored. Gas/water interfaces (in the form of air bubbles or foam) are detrimental to 
the stability of proteins, often causing aggregation. This represents a potential problem for 
industrial processes, e.g., the production and handling of protein drugs.1-3 We use HDX-
MS for probing the conformational dynamics of the model protein Mb in the presence of 
N2 bubbles. The conformational dynamics of the model protein myoglobin under N2 
sparging condition is explored by HDX-MS, and an interesting EX1 behavior is observed. 
This event reflects the interconversion of the native state with conformers that are globally 
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unfolded and long-lived. In contrast to this, EX2 dynamics take place in the bubble-free 
environment and suggest the occurrence of short-lived excursions to partially unfolded 
conformers. A simple model is built to describe the observation: “semi-unfolded”  
“native”  “globally unfolded”  “aggregated”. To our knowledge, this is the first time 
HDX-MS is applied to explore the surface denaturation of proteins. 
One of the most widely used applications of HDX-MS is to probe how protein dynamics 
change as a result of protein-ligand interactions. Chapter 3 conducts a detailed analysis of 
a vital protein system that regulates osteoclastogenesis: OPG/RANKL/HS.4,5 In brief, OPG 
exist simultaneously as monomer (OPGSH) and covalently linked dimer form (OPG2SS). 
Both forms are capable of blocking RANKL from deactivating bone resorption 6,7 and the 
dimerization can be regulated by HS.8 HDX-MS data reveal the dynamics changes of OPG 
oligomers under various ligand conditions and shows RANKL and HS have different 
effects on OPGSH and OPG2SS. The effect induced by RANKL on OPGSH is rather weak 
but can be strengthened with HS. We also proposed a model to explain the RANKL and 
HS binding mechanism on OPG. One of the challenges in this project is the absence of 
structural information on full-length (untruncated) OPG. This Chapter particularly 
highlights the advantages of HDX-MS as providing structural information that was not 
available before.  
Allosteric proteins possess dynamically coupled residues for the propagation of input 
signals to distant target binding sites. The input signals usually correspond to “effector is 
present” or “effector is not present”. Many aspects of allosteric regulation remain 
incompletely understood. Chapter 4 focuses on S100A11, a dimeric EF-hand protein with 
two hydrophobic target binding sites. An annexin peptide (Ax) served as the target. Target 
binding is allosterically controlled by Ca2+ which promotes the formation of a [Ca4 S100 
Ax2] complex. Ax peptides are accommodated between helices III/IV and III’/IV’. Without 
Ca2+ these binding sites are closed, precluding interactions with Ax. The allosteric 
mechanism was probed by microsecond MD simulations in explicit water, complemented 
by HDX-MS. Consistent with experimental data, MD runs in the absence of Ca2+ and Ax 
culminated in target binding site closure. In simulations on [Ca4 S100] the target binding 
sites remained open. These results capture the essence of allosteric control, revealing how 
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Ca2+ prevents binding site closure. Both HDX-MS and MD data showed that the metalation 
sites become more dynamic after Ca2+ loss. However, these enhanced dynamics do not 
represent the primary trigger of the allosteric cascade. Instead, a labile salt bridge (K32-
D57) acts as an incessantly active “agitator” that destabilizes the packing of adjacent 
residues, causing a domino chain of events that culminates in target binding site closure. 
This agitator represents the starting point of the allosteric signal propagation pathway. Ca2+ 
binding rigidifies elements along this pathway, thereby blocking signal transmission. This 
newly discovered mechanism differs from the conventional view that allosteric effects 
always start from the effector binding site. It remains to be seen in how far this novel 
paradigm can be extended to other allosteric regulation events. 
 
5.2  Future Directions 
 
5.2.1  HDX-MS on Membrane Proteins 
 
Membrane proteins are fascinating to study since they carry critical function in living 
organisms. They are the channels for cells and organelles to link outside and inside 
environments. They are also the binding sites for over 50% of modern drugs.9 However, 
membrane proteins continue to pose challenges to biochemistry and biology due to their 
hydrophobic nature. The 3D structures of many membrane proteins are still not available. 
That makes HDX-MS a promising tool to study membrane protein since there is no 
prerequisite for structural information.  
Recent attempts to apply HDX-MS to membrane proteins have achieved success to a 
certain extent.10 Many detergents (e.g., n-dodecyl-β-D-maltopyranoside, n-Octyl-β-d-
glucopyranoside) are used to enhance solubility and digestion of membrane proteins. But 
to date, no systematic research has been done on how to apply detergents in HDX-MS 
properly. Guidelines and tips and are scattered across various papers or kept as “secrets” in 
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different laboratories. A universal protocol needs to be established for high throughput 
investigations. 
Also, how detergents affect protein structure and conformations is still a question that 
remains quite controversial. Generally, nonionic detergents are considered to be “mild” for 
proteins. But how “mild” these detergents are and whether these detergents would cause 
artifacts is still unknown. It would be interesting to use HDX-MS to examine the dynamic 
changes induced by detergents on one or several model proteins, such as bacteriorhodopsin. 
The results of such studies can benefit HDX field and guide future investigations on 
membrane proteins. 
 
 
5.2.2 HDX-MS on the OPG/RANKL/RANK System 
 
Chapter 3 in this dissertation concentrates on dynamics changes of OPG under different 
circumstances. However, we must keep it in mind that OPG is only part of the 
osteoclastogenesis regulatory system. The dynamics changes on RANKL in OPG-RANKL 
were not investigated. Further, it would be interesting to check the dynamics difference on 
RANKL between two complexes: OPG-RANKL and RANK-RANKL. Such experiments 
could potentially provide significant insights into bone metabolism, and they could help 
therapeutic developments for osteoporosis and osteoproliferation.  
 
5.2.3 Computational Simulation of the HDX Process 
 
The actual exchange between hydrogen and deuterium at amide backbone sites still can not 
be simulated by MD methods or related computational tools. This much limits the 
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capability of MD simulations to reappear reproduce or predict the result of HDX 
experiments. Classical MD simulations are unsuitable for modeling HDX events at an 
atomistic level because typical force fields do not allow the dissociation or formation of 
covalent bonds. However, with hybrid quantum-mechanical/molecular-dynamics 
(QM/MD) techniques atomistic simulations of HDX experiments may become 
achievable.11 In this case, heavy atoms of the protein will still be treated by classical MD 
simulations. Simultaneously, exchange events between hydrogens on the protein and 
deuterium in the aqueous/gas phase will be simulated by quantum mechanical or density-
functional theory (DFT)-based methods. It is foreseeable that the development of such 
methods will be a time-consuming process. However, the application prospects of such 
method are enormous, as they would provide a truly comprehensive view of protein HDX 
events, perhaps resulting in novel paradigms for the interpretation of experimental HDX 
data. 
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